Supplementary Materials

Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial.

Authors
K. Baksaas-Aasen*[1] MD, L. S. Gall*[2] PhD, J. Stensballe[3] PhD, N.P. Juffermans[4] Prof, N. Curry[5] MD, M. Maegele[6] Prof, A. Brooks[7] MD, C. Rourke[2] BSc, S. Gillespie[2] PhD, J. Murphy[8] MSc, R. Maroni[8] MSc, P. Vulliamy[2] PhD, H. H. Henriksen[3] MD, K. Holst Pedersen[3] MSc, K. M. Kolstadbraaten[1] MSN, M. R. Wirtz[4] MD, D. J. B. Kleinveld[4] MD, N. Schäfer[6] PhD, S. Chinna[7] MB ChB, R. A. Davenport[2] PhD, P.A. Naess[1] Prof, J.C. Goslings[4] Prof, S. Eaglestone[2] PhD, S. Stanworth[5] Prof, P. I. Johansson[3] Prof, C. Gaarder[1] Prof, K. Brohi[2] Prof.
*These authors contributed equally to the study

1. Oslo University Hospital, Oslo, Norway and Faculty of Medicine, University of Oslo, Norway
2. Centre for Trauma Sciences, Queen Mary University of London, London, United Kingdom
3. Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
4. Amsterdam University Medical Centres, Amsterdam, The Netherlands
5. Oxford University Hospital NHS Trust, John Radcliffe Hospital, Oxford, United Kingdom
6. Cologne- Merheim Medical Centre, University of Witten/Herdecke, Cologne, Germany
7. Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
8. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

Corresponding author:
Karim Brohi, Centre for Trauma Sciences, Queen Mary University of London,
4 Newark Street, London, E1 2AT, United Kingdom.
E-mail: k.brohi@qmul.ac.uk

Table S1 Interventions & 24-hour transfusion requirements

Subgroup	% receiving study intervention^	Time to 1st study intervention (mins)	RBCs (units)	FFP/Octaplasma (units)	Fibrinogen equivalent (g)	Platelets (pools)
Baseline to Haemostasis						
All – Intention-to-treat (n with haemostasis = 348)						
CCT	62/170 (36%)	80 (60-106)	3 (1-6)	4 (2-6)	0 (0-4)	1 (0-1)
VHA	120/178 (67%)**	61 (48-85)*	3 (1-6)	4 (1-6)	4 (0-4)*	1 (0-2)**
Per protocol (n with haemostasis = 286)						
CCT	59/148 (40%)	79 (56-107)	3 (2-6)	4 (2-7)	0 (0-4)	1 (0-2)
VHA	108/138 (78%)**	64 (46-85)*	4 (1-6)	4 (2-7)	4 (0-4)*	2 (1-2)**
Severe TBI (n with haemostasis = 63)						
CCT	6/26 (23%)	61 (34-101)	2 (0-3)	3 (1-6)	0 (0-0)	0 (0-1)
VHA	26/37 (70%)**	53 (45-85)	3 (1-6)*	3 (1-6)	4 (0-4)*	2 (0-2)*
No/Mild TBI (n with haemostasis = 281)						
CCT	56/142 (40%)	80 (62-109)	3 (2-6)	4 (2-7)	0 (0-4)	1 (0-1)
VHA	93/139 (67%)**	64 (50-85)*	3 (1-6)	4 (1-6)	2 (0-4)	1 (0-2)*
Injury to 24 hours						
All – Intention-to-treat (n = 396)						
CCT	86/195 (44%)	187 (143-234)	6 (4-10)	7 (4-11)	3 (0-4)	1 (0-2)
VHA	139/201 (69%)**	164 (130-194)*	6 (3-10)	6 (3-10)*	4 (0-4)	2 (1-3)*
Per protocol (n = 313)						
CCT	79/163 (48%)	189 (143-232)	6 (4-11)	8 (4-12)	4 (0-4)	1 (0-2)
VHA	122/150 (81%)**	164 (127-195)*	6 (4-10)	6 (4-10)	4 (0-8)*	2 (1-3)*
Severe TBI (n = 74)						
CCT	12/35 (34%)	153 (111-222)	6 (4-10)	6 (2-9)	0 (0-4)	1 (0-2)
VHA	29/39 (74%)**	144 (118-197)	6 (4-8)	4 (4-8)	4 (0-4)	2 (1-3)*
No/Mild TBI (n = 313)						
CCT	73/156 (47%)	191 (152-233)	6 (4-10)	8 (4-12)	4 (0-4)	1 (0-2)
VHA	108/157 (69%)**	164 (133-190)*	6 (3-10)	6 (3-10)*	4 (0-5)	2 (1-3)

The results are given as median (interquartile range), except for % receiving study intervention. Data for Baseline to Haemostasis does not include patients who died before haemostasis. Transfusion components are the total number of components given, both empiric and study directed. The statistical comparisons in this table are all post-hoc analyses, except for those for the RBCs, FFP/Octaplasma and platelets in the ITT cohort. A correction for multiple testing has not been applied.

A small number of patients in each subgroup did not have a record for all measures (missing numbers not shown). In the ITT cohort, the number of missing records reached 9% for some of the measures.

^ Results given as number/number in subgroup (percentage).
* p-value for the difference between the two groups of less than 0.05
** p-value for the difference between the two groups of less than 0.001

RBC Red Blood Cell, FFP Fresh Frozen Plasma, CCT Conventional Coagulation Test, VHA Viscoelastic Haemostatic Assay, PTr Prothrombin Time ratio, TBI Traumatic Brain Injury

Fig. S1 28-day mortality in pre-specified subgroups

Subgroup	No. patients	No. deaths(%) CCT	No. deaths(%) VHA		Odds Ratio (95% CI)	p-value interaction
PTr > 1.2 at baseline						0.070
Yes	102	32/58 (55)	18/44 (41)		0.56 (0.26, 1.24)	
No	253	16/122 (13)	24/131 (18)		1.49 (0.75, 2.93)	
Massive transfusion						0.467
Yes	108	26/55 (47)	20/53 (38)		0.68 (0.32, 1.45)	
No	287	29/139 (21)	30/148 (20)		0.96 (0.55, 1.70)	
Severe TBI						0.016
Yes	73	25/34 (74)	17/39 (44)		0.28 (0.10, 0.74)	
No	313	29/156 (19)	32/157 (20)		1.12 (0.64, 1.95)	
Prior oral anticoagulants						0.546
Yes	27	6/15 (40)	3/12 (25)		0.50 (0.10, 2.49)	
No	362	49/176 (28)	46/186 (25)		0.85 (0.53, 1.36)	
Per Protocol	312	41/162 (25)	31/150 (21)		0.77 (0.45, 1.30)	
Overall (all patients)	395	55/194 (28)	50/201 (25)		0.84 (0.54, 1.31)	

```
        0.1      0.2    0.4  0.6 0.8 1.0    2.0   3.0 4.0

              VHA better          CCT better
```

Odds ratios for 28-day mortality outcome at day 28 in the subgroups of coagulopathic patients at baseline (defined as PTr > 1.2), patients receiving massive transfusion, patients with severe TBI, patients with prior oral anticoagulants, the Per Protocol and Intention-To-Treat (Overall) populations. Odds ratios were calculated using the VHA arm as the exposed group.

One patient in the CCT arm had unknown outcome at 28 days, so the total number of patients is 395. Subgroup allocation criteria were missing for some patients, so some subgroups do not add up to 395 patients. In particular, including the one patient with unknown outcome at 28 days, the following patients had missing data in their records: 40 did not have a PTr value at baseline, 9 did not have a TBI score, 6 did not have a record for prior oral anticoagulants.

The solid black line indicates an odds ratio of 1, equivalent to no difference between study groups. The vertical red dashed line indicates the overall odds ratio for the ITT population.

Post-hoc analysis: the p-values for the interaction between study arm and each subgroup were calculated using a logistic regression with mortality at 28 days as the outcome.

CI Confidence Interval, CCT Conventional Coagulation Test, VHA Viscoelastic Haemostatic Assay, PTr Prothrombin Time ratio, TBI Traumatic Brain Injury, ITT Intention-To-Treat.

Table S2 Admission characteristics in severe TBI predefined subgroup (intention-to-treat)

	CCT (n = 35)	VHA (n = 39)
Median age (IQR)+	39 (26-54), n = 35	40 (24-56), n = 39
Male sex – no. (%)+	29/35 (83%)	22/39 (56%)
Injuries & Admission Physiology		
Median Injury Severity Score (IQR)	38 (29-43), n = 35	41 (34-54), n = 39
Injury caused by blunt trauma alone – no. (%)	25/35 (71%)	30/39 (77%)
Median heart rate (IQR) – beats/min	90 (75-110), n = 31	112 (87-128), n = 37
Median systolic blood pressure (IQR) – mmHg	87 (58-100), n = 28	80 (60-120), n = 35
Median Glasgow Coma Scale score (IQR)	3 (3-3), n = 34	3 (3-6), n = 39
Median Base Deficit (IQR) – mEq/L	8.7 (4.0-13.9), n = 34	10.1 (7.9-16.3), n = 36
Median Lactate (IQR) – mEq/L	5.2 (3.0-10.5), n = 34	5.3 (3.3-8.7), n = 38
Admission Coagulation Profile		
Patients with PTr > 1.2 – no. (%)	15/32 (47%)	16/35 (46%)
Median fibrinogen (IQR) – g/L	1.4 (1.1-2.1), n = 30	1.5 (0.9-2.1), n = 34
Pre-baseline therapy		
Received tranexamic acid bolus – no. (%)	33/35 (94%)	35/39 (90%)
Median units of RBCs (IQR)	3 (1-4), n = 31	2 (1-4), n = 37
Median units of FFP/Octaplasma (IQR)	0 (0-3), n = 31	0 (0-2), n = 37
Median equivalent dose of fibrinogen (IQR) – g	0 (0-0), n = 32	0 (0-0), n = 35
Median units of Platelets (IQR)	0 (0-0), n = 31	0 (0-0), n = 37

TBI Traumatic Brain Injury, CCT Conventional Coagulation Test, VHA Viscoelastic Haemostatic Assay, IQR Interquartile Range, AIS Abbreviated Injury Scale, RBC Red Blood Cells, FFP Fresh Frozen Plasma. PTr Prothrombin Time ratio.

Table S3 Adjusted analysis of the severe TBI subgroup

	Alive and Free of Massive Transfusion at 24 Hours (Primary Endpoint)	28-day Mortality
Un-Adjusted	OR = 2.12 (95% CI 0.83-5.39)	OR = 0.28 (95% CI 0.10-0.74)
Univariate Adjusted		
Age	OR = 2.53 (95% CI 0.91-7.09)	OR = 0.28 (95% CI 0.10-0.74)
Sex	OR = 1.92 (95% CI 0.73-5.06)	OR = 0.30 (95% CI 0.11-0.82)
Type of Injury (blunt/penetrating)	OR = 2.26 (95% CI 0.87-5.88)	OR = 0.25 (95% CI 0.09-0.69)
Heart Rate at admission	OR = 1.59 (95% CI 0.57-4.42)	OR = 0.33 (95% CI 0.11-0.97)
Systolic Blood Pressure at admission	OR = 1.53 (95% CI 0.54-4.31)	OR = 0.26 (95% CI 0.08-0.81)
Glasgow Coma Scale score at admission	OR = 2.00 (95% CI 0.78-5.12)	OR = 0.21 (95% CI 0.07-0.64)
Base Deficit at admission	OR = 2.74 (95% CI 0.96-7.77)	OR = 0.21 (95% CI 0.06-0.68)
Multivariate Adjusted (all of the covariates above)	OR = 2.10 (95% CI 0.51-8.61)	OR = 0.16 (95% CI 0.03-0.90)

Odds ratios for the primary outcome (alive and free of massive transfusion at 24 hours) and 28-day mortality in the subgroup of patients with severe TBI, risk adjusted for admission characteristics. Odds ratios were calculated using the VHA arm as the exposed group.

Queen Mary
University of London

Barts Health **NHS**
NHS Trust

iTACTIC: Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy

A multi-centre, prospective, randomized controlled study to compare outcomes of viscoelastic haemostatic assay (VHA)-guided resuscitation versus optimised conventional coagulation test (CCT) resuscitation support in haemorrhaging trauma patients.

CLINICAL TRIAL PROTOCOL
BARTS HEALTH NHS TRUST

	NUMBER	DATE
VERSION	3.0	14/03/2017
AMENDMENTS		

Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy

A multi-centre, prospective, randomized controlled study to compare outcomes of viscoelastic haemostatic assay (VHA)-guided resuscitation versus optimised conventional coagulation test resuscitation support in haemorrhaging trauma patients.

Short title/Acronym: iTACTIC

Sponsor Queen Mary, University of London

Contact person of the above sponsor organisations is:

Dr Sally Burtles
Director of Research Services & Business Development
Joint Research Management Office
QM Innovation Building
5 Walden Street
London E1 2EF
Phone: 020 7882 7260
Email: sponsorsrep@bartshealth.nhs.uk

REC Reference 16/LO/0004

Chief Investigator: Professor Karim Brohi
Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, 4 Newark Street, Whitechapel, London, E1 12AT, UK
Phone: +44 77 0319 0545
Email: k.brohi@qmul.ac.uk

REC reference: 16/LO/0004

EudraCT reference: *Insert once known*

Study sites: Academic Medical Centre, Amsterdam, The Netherlands

Kliniken der Stadt Köln gGmbH, Cologne, Germany

Rigshospitalet (Copenhagen University Hospital), Copenhagen, Denmark

John Radcliff Hospital, Oxford, United Kingdom

Oslo University Hospital, Oslo, Norway

The Royal London Hospital, London, United Kingdom

Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, London, United Kingdom

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom

Nottingham University Hospitals Queens Medical Centre, Nottingham, UK

Radboud university medical center, Nijmegen, Netherlands

University of Kansas Hospital (UKH), Kansas City, USA

CONTENTS PAGE

1. GLOSSARY OF TERMS AND ABBREVIATIONS

APTT	Activated Partial Thromboplastin Time
AE	Adverse Event
AR	Adverse Reaction
AUC	Area Under the Curve
CCT	Conventional Coagulation Tests
CI	Chief Investigator
CRF	Case Report Form
CTIMP	Clinical Trial of an Investigational Medicinal Product
DMC	Data Monitoring Committee
EC	European Commission
EMEA	European Medicines Agency
EU	European Union
EudraCT	European Union Drug Regulating Authorities Clinical Trials
FiO2	Fraction of inspired Oxygen
FFP	Fresh Frozen Plasma
PaO2	Partial pressure of arterial Oxygenation
GCP	Good Clinical Practice
GCS	Glasgow Coma Score
ICU	Intensive Care Unit
ISRCTN	International Standard Randomised Controlled Trial Number
JRMO	Joint Research Management Office
MTP	Massive Transfusion Protocol
PC	Personal Consultee
PI	Principle Investigator
PTr	Prothrombin Time / International Ratio (PT/INR)
QALY	Quality Adjusted Life Years
QMUL	Queen Mary University of London
QoL	Quality of Life
RBC	Red Blood Cells
RCT	Randomised Controlled Trial
REC	Research Ethics Committee
ROTEM	Rotational Thromboelastometry
RRR	Relative Risk Reduction

SAE	Serious Adverse Event
SAR	Serious Adverse Reaction
SOFA	Sequential Organ Failure Assessment
SOP	Standard Operating Procedure
Subject	An individual who takes part in a clinical trial
SUSAR	Suspected Unexpected Serious Adverse Reaction
TEG	Thromboelastography
TIC	Trauma Induced Coagulopathy
VHA	Viscoelastic Haemostatic Assays

2. SIGNATURE PAGE

Chief Investigator Agreement

The clinical study as detailed within this research protocol **(Version 3.0, dated 14 Mar 17)**, or any subsequent amendments will be conducted in accordance with the Research Governance Framework for Health & Social Care (2005), the World Medical Association Declaration of Helsinki (1996) and the current applicable regulatory requirements and any subsequent amendments of the appropriate regulations.

Chief Investigator Name: Professor Karim Brohi

Chief Investigator Site: Royal London Hospital, Barts Health NHS Trust

Signature and Date:

Principal Investigator Agreement *(if different from Chief investigator)*

The clinical study as detailed within this research protocol **(Version 3.0, dated 14 Mar 17)**, or any subsequent amendments will be conducted in accordance with the Research Governance Framework for Health & Social Care (2005), the World Medical Association Declaration of Helsinki (1996) and the current applicable regulatory requirements and any subsequent amendments of the appropriate regulations.

Principal Investigator Name: Professor Karim Brohi

Principal Investigator Site: Royal London Hospital, Barts Health NHS Trust

Signature and Date:

3. SUMMARY

General Information

This document was constructed using the Non-CTIMP Protocol Template (V3.0, 15 Nov 2012 Final JMRO Master Template). It describes a comparison of viscoelastic haemostatic assay-led resuscitation versus conventional resuscitation support in haemorrhaging trauma patients in a Phase 2a multi-site randomized control trial, and provides information for entering patients/subjects into it. The protocol should not be used as a guide for the treatment of other patients. Every care has been taken in drafting this protocol, but corrections or amendments may be necessary. These will be circulated to the registered investigators in the trial, but those entering participants for the first time are advised to contact the Trial Manager to confirm they have the most up to date version.

Compliance

The trial will be conducted in compliance with the approved protocol, the Declaration of Helsinki (2008) the Principles of Good Clinical Practice (GCP), European Commission Directive 2005/28/EC with the implementation in national legislation in the UK by Statutory Instrument 2004/1031 and subsequent amendments, the UK Data Protection Act and the National Health Service Research Governance Framework for Health and Social Care.

Sponsor

Queen Mary University of London (QMUL) is the trial sponsor. Queries relating to the QMUL sponsorship of the trial should be addressed to the Director of Research Services & Business Development, Dr Sally Burtles, JRMO, QMUL Innovation Department, 5 Walden Street, London, E1 2EF, E-mail: sponsorsresp@bartshealth.nhs.uk, or via the trial manager.

Funding

This trial is part-funded by the European Commission under the HEALTH-Contract No. F3-2013-602771, entitled "Targeted Action for Curing Trauma Induced Coagulopathy" (TACTIC).

TITLE	A multi-centre, prospective, randomized controlled study to compare outcomes of viscoelastic haemostatic assay (VHA)-guided resuscitation versus optimised conventional coagulation test resuscitation support in haemorrhaging trauma patients.
SHORT TITLE	Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy (iTACTIC)
PROTOCOL VERSION/DATE	v3.0 / 14/03/2017
METHODOLOGY	Non-blinded, randomised controlled trial
STUDY DURATION	The study will enrol patients over a 24-month period. Patient follow-up, data cleaning & analysis will take a further 9 months.
TREATMENT DURATION	The subject's participation in the study will last a maximum of 28 days.
STUDY LEADS	CHIEF INVESTIGATOR: Prof Karim Brohi Centre for Trauma Sciences, Blizard Institute Queen Mary University of London, 4 Newark Street, London, E1 2AT Phone: +44 7703 190545 Email: k.brohi@qmul.ac.uk CO-INVESTIGATOR: Dr Christine Gaarder Department of Traumatology, Oslo University Hospital, 166 Kirkeveien, Oslo, NO-0424 Phone: +47 4131 8992 Email: tinagaa@ous-hf.no
PRIMARY OBJECTIVE	The primary objective is to compare the haemostatic effect of Viscoelastic Haemostatic Assays (VHA)-guided transfusion strategy versus optimized non-VHA guided transfusion strategy in haemorrhaging trauma patients.
SECONDARY OBJECTIVES	The secondary objectives of the study are to determine the effects of VHA-led versus optimized non-VHA guided resuscitation on organ failure, hospital stay, critical care stay, health care resource needs and mortality.
PHASE OF THE TRIAL	Phase 2a

NUMBER OF SUBJECTS	A total target of 392 adult male and female severely injured trauma patients with ongoing traumatic haemorrhage.
INCLUSION CRITERIA	**INCLUSION CRITERIA** A patient will be eligible for the study if they meet the following criteria: • Adult trauma patients (according to local definitions) • Present with clinical signs of haemorrhagic shock AND • Activate the local massive haemorrhage protocol and initiate first transfusion • Randomised within 3 hours of injury and 1 hour of admission to the emergency department of the participating study site • Agreement is provided on behalf of incapacitated patients by Personal Consultee or Nominated Consultee (i.e. trauma team leader)
STATISTICAL METHODOLOGY AND ANALYSIS	**ANALYSIS POPULATIONS:** The analysis populations will be defined as follows: *Intention to treat analysis* All patients randomized will be analysed according to the treatment arm to which they are assigned. *Per protocol analysis* The following patients will be excluded from the per protocol analysis: • Patients who do not have at least one VHA or Conventional Coagulation Test (CCT) performed • Patients who die within 60 minutes after baseline blood sampling • Patients who achieve haemostasis within 60 minutes of baseline sampling. **PRIMARY ENDPOINT ANALYSIS:** Difference in proportion will be examined with the Chi-square test. Absolute and Relative Risk Reductions will be calculated. **SECONDARY VARIABLES ANALYSES:** Difference in proportions will be examined with the Chi-square test. Differences between continuous variables will be assessed by difference in means and the Students-t test, or

	difference in median and the Mann-Whitney U test as appropriate.
Proposed Start Date	1st December 2015
Proposed End Date	30th November 2017
Study Duration	24 months

SAE REPORTING

Within 24 hours of becoming aware of a reportable SAE please fax a completed SAE form to the Sponsor on:

+44 20 7882 7276

Or E-mail information to: **research.safety@bartshealth.nhs.uk**

4. INTRODUCTION

4.1 BACKGROUND

Traumatic injury is responsible for a large and increasing proportion of the world's burden of disease and is the 4th leading cause of death globally [1]. Half of all trauma deaths are due to bleeding and most of these will occur within 6 hours from injury [2]. Hemorrhagic shock following injury has been shown to induce a clotting dysfunction (i.e. coagulopathy) within minutes [3-5].

Such early trauma induced coagulopathy (TIC) may exacerbate bleeding and is associated with higher mortality and morbidity [4,6,7]. Many more injured patients will go on to develop different types of coagulopathy at different times during the course of their treatment, either as a result of their body's on-going response to trauma or as a consequence of their clinical care. Ultimately coagulopathic, hemorrhaging trauma patients have increased blood transfusion requirements, increased mortality and more adverse outcomes [8].

Despite improvements in surgical techniques, resuscitation strategies and intensive care treatments, outcomes for critically injured patients remain poor with severe bleeding, brain injury, tissue damage and multiple organ failure linked to high mortality [9]. Within the last decade research focusing on TIC has led to improved resuscitation strategies, resulting in the early and more aggressive use of blood products and coagulation factors for the management of massively bleeding patients.

4.2 CLINICAL DATA

In spite of improved resuscitation strategies, current transfusion therapy still fails to correct coagulopathy during ongoing haemorrhage [10]. The mechanisms and genesis of TIC have yet to be fully elucidated, and there are many questions around how to optimally diagnose, resuscitate and monitor the critically bleeding trauma patient.

It is important to detect TIC as early as possible. Conventional coagulation tests (CCT), such as prothrombin time/international ratio (PT/INR), activated partial thromboplastin time (APTT), fibrinogen concentration and platelet counts, have traditionally been used. However, there is a striking lack of evidence to support the use of these CCT to monitor resuscitation, although threshold triggers for intervention based on CCT have been suggested [5].

Recent published evidence describes an increasing recognition for the potential of the two current market-leading Viscoelastic Haemostatic Assays (VHAs) namely Thromboelastography (TEG®; Haemonetics Incorporation) and Rotational Thromboelastometry (ROTEM®; TEM Innovation GmbH). Both platforms use similar test modes to rapidly and accurately determine the functional coagulation status of patient whole blood *(see Figure 1)*.

***Figure 1** – **Viscoelastic Haemostatic Assay (VHA) systems**: In TEG a pin attached to a torsion wire is immersed in an oscillating cup containing the blood sample at 37ºC. Conversely in ROTEM the cup is stationary and the oscillating pin is attached to an optical detector. As clot forms, the gap between cup and pin is bridged and the oscillation is transmitted from the cup to the pin (TEG), or impedes rotation of the pin (ROTEM).*

The relative contribution of blood components such as fibrinogen and platelets to clot strength can be evaluated through the use of specific inhibitors or agonists. The viscoelastic properties of blood samples are recorded under low shear conditions, thereby providing a comprehensive visual profile (see *Figure 2*) of clot formation and breakdown (fibrinolysis).


Figure 2 – **TEG® and ROTEM® measurements.** *Oscillation is detected and a characteristic trace generated, with a profile reflecting different aspects (parameters) of coagulation: TEG®: R, Reaction time; Angle; MA, Maximum Amplitude; Ly30, hyperfibrinolysis after 30 min. ROTEM®: CT, Clotting Time; A10;, Amplitude after 10 min; MCF, Maximum Clot Firmness; Li30, hyperfibrinolysis after 30 min.*

VHA may be performed at the point-of-care to provide clinically relevant results within a 5-10 minute timeframe and thus may be repeated in a massive bleeding situation to guide the transfusion. Furthermore as well as the benefit of rapid readout, VHAs provide a functional description of coagulation status unlike existing CCTs (e.g. the potential to detect hyperfibrinolysis).

Whilst VHA has been used for many years in liver transplant and cardio-pulmonary surgery, there remains the absence of robust data supporting its universal uptake in the context of trauma. Whilst some publications have attempted to identify VHA-patterns and thresholds characterizing TIC and need for massive transfusion in trauma patients, definitive evidence proving its superiority over CCTs in the diagnosis and management of coagulopathy in the acute setting is not conclusive [11,12].

4.3 RATIONALE AND RISKS/BENEFITS

Although considered a preventable major cause of death, the management of coagulopathic bleeding in trauma patients remains primarily based upon retrospective registry studies of survival and extrapolating the results of transfusion practice performed in the elective, non-acute surgical setting. Treatment is diverse comprising the empiric transfusion of red blood cells (RBC) and clotting product supplements to patients, blind to the type and severity of TIC they may have - or indeed even if they do not have coagulopathy.

It is well established that blood transfusion carries significant health risks both related to transmission of pathogens and to the development of transfusion reactions. Published in 2015, the results of the Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial [13] provide the best evidence to date for optimal

trauma haemorrhage resuscitation. PROPPR demonstrated that an empiric massive transfusion protocol (MTP) aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) administered from the early phase of care and during on-going haemorrhage was associated with better outcome than a 1:1:2 ratio.

This prospective randomized controlled trial (RCT) will employ evidence-based treatment algorithms to compare outcomes of VHA-guided resuscitation versus CCT resuscitation support in haemorrhaging trauma patients.

The hypothesis for this comparative study is that VHA-directed therapy will enhance early hemostatic control by the targeted correction of TIC, whilst also reducing the blind administration of blood products and procoagulants to all bleeding trauma patients, including those not having TIC. This would significantly reduce both the number of patients receiving blood transfusion and the number of transfused blood products per transfused patient, thereby improving both patient safety and resource utilization.

5. TRIAL OBJECTIVES

5.1 PRIMARY OBJECTIVE

The primary objective is to compare the haemostatic effect of viscoelastic haemostatic assay-guided transfusion strategy versus optimized CCT guided transfusion strategy in haemorrhaging trauma patients.

5.2 SECONDARY OBJECTIVE

The secondary objectives of the study are to determine the effects of VHA-led versus optimized CCT guided resuscitation on organ failure, hospital stay, critical care stay, health care resource needs and mortality.

5.3 PRIMARY ENDPOINT

The primary endpoint is the proportion of subjects alive and free of massive transfusion* at 24 hours.

* receiving 10 or more units of RBC within 24 hours

5.4 SECONDARY ENDPOINTS

The secondary end points listed below will be analysed in order to provide a sensitive and comprehensive description of outcomes and healthcare resource demands for the VHA and CCT arm subjects:

- All-cause mortality at 6 and 24-hours and 28 & 90-days post admission

- Duration and severity of coagulopathy until haemostasis, as defined by the area under the time[1] multiplied by PTr curve [2,3]

- Proportion of patients who have corrected coagulopathy after first 8 units of RBC

- Time to haemostasis[1]

- Time spent in coagulopathic condition until haemostasis[1]

- Blood products (RBC, plasma, platelets alone and in total) first 6 and 24 hours after admission

- 28-day ventilator free days

- 28-day ICU-free days

- Total hospital length of stay

- 28-day symptomatic thromboembolic events

- Incidence of transfusion related complications

- Incidence of organ dysfunction

- Health care resource, productivity costs and HRQoL (EuroQol EQ-5D™ at discharge or day 28, and at day 90)

- Lifetime health economic cost-effectiveness of personalized VHA-guided haemorrhagic treatment versus MTP-based on best practice and CCT

[1]Time of haemostasis is defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary haemostasis has been achieved

[2]Coagulopathy defined as PTr >1.2

[3]Patients who die will have their time of haemostasis set at 24 hours, and last PTr extrapolated to this time point.

Note: All non-survivors (patients who die during the 28-day study period) will receive 0 days for Hospital-free days.

6. METHODOLOGY

6.1 INCLUSION CRITERIA

Adult trauma patients (according to local definitions) will be enrolled if they satisfy each of these inclusion criteria:

- Present with clinical signs of haemorrhagic shock
- Activate the local massive haemorrhage protocol and initiate first transfusion

- Randomised within 3 hours of injury and 1 hour of admission to the ED of the participating study site

- Agreement is provided on behalf of incapacitated patients by Personal Consultee or Nominated Consultee (i.e. trauma team leader)

6.2 EXCLUSION CRITERIA

Patients will be ineligible to be enrolled in the study if:

- Any inclusion criteria are not met

6.3 STUDY DESIGN

This randomised controlled study will follow the clinical course of haemorrhaging trauma patients on admission to the ED and for up to 28 days thereafter. Only injured patients suffering haemorrhage and shock will be considered for enrolment into the study which will, of necessity, include patients who are unable to give consent for themselves (see *Section 9.5.1*).

CCT
The CCT arm in this randomised controlled trial will comprise treatment according to an optimized MTP guided by CCTs (see *Section 7.5.4*) based upon current published evidence and empiric best practice according to the PROPPR and CRASH-2 trials data (i.e. 1:1:1 product ratio, with the anti-fibrinolytic Tranexamic Acid (TXA)) [13-15].

VHA
The VHA arm will employ an evidence-based algorithm for VHA-directed treatment (see *Section 7.5.5*) based upon current published evidence and empiric best practice according to the PROPPR and CRASH-2 trials data (i.e. 1:1:1 product ratio, with the anti-fibrinolytic Tranexamic Acid (TXA)) [13-15].

This VHA treatment algorithm is based upon analysis of more than 2,200 trauma subjects enrolled to a prospective observational study conducted at the participating study sites, entitled Activation of Coagulation and Inflammation in Trauma (ACIT) [10]. Analysis of the ACIT dataset has enabled the definition of clinically-relevant VHA thresholds and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been applied to the generation of an evidence–based targeted treatment algorithm, which will be used to treat the interventional group and compared with patients receiving optimized MTP care alone.

6.4 STUDY SCHEME

```
                    ┌─────────────────────────────┐
                    │  Trauma patient admitted to  │
                    │   Emergency Department       │
                    └─────────────────────────────┘
                                  │
                                  ▼
                    ┌─────────────────────────────┐         ┌──────────────────┐
                    │    Screened for eligibility  │         │ Screening data   │
                    │ If eligible, consent or      │         │ collection       │
                    │ agreement to participate     │         └──────────────────┘
                    │ sought.                      │
                    └─────────────────────────────┘
                                  │                          ┌──────────────────┐
                                  ▼                          │ Enrolment        │
      ┌────────┐       ┌─────────────────────────┐           └──────────────────┘
      │  NO    │◄──────│  Consent or agreement    │
      └────────┘       │  obtained?               │
          │            └─────────────────────────┘
          ▼                       │
┌─────────────────────┐      ┌────────┐
│ Continue standard   │      │  YES   │
│ management          │      └────────┘
└─────────────────────┘          │
                                 ▼                           ┌──────────────────┐
                    ┌─────────────────────────────┐          │ Allocation       │
                    │   Participant randomised     │          └──────────────────┘
                    │   Patient registration.      │
                    │   Unique study ID            │
                    └─────────────────────────────┘
                      │                         │
                      ▼                         ▼
          ┌────────────────────┐     ┌────────────────────┐
          │ VHA Group          │     │ CCT Group          │
          │ VHA-led therapy    │     │ CCT-led therapy    │
          └────────────────────┘     └────────────────────┘
                  Intervention
                      │                         │
                      ▼                         ▼
                ┌─────────────────────────────┐          ┌──────────────────┐
                │  Completion of participation │          │ Outcome data     │
                │  Discharge from hospital,    │          │ collection       │
                │  death or Day28              │          └──────────────────┘
                └─────────────────────────────┘
                              │
                              ▼
                ┌─────────────────────────────┐
                │  Primary outcome             │
                │  Haemostasis                 │
                └─────────────────────────────┘
                              │
                              ▼
                ┌─────────────────────────────┐
                │  Secondary outcome           │
                │  Clinical outcomes &         │
                │  resource demands            │
                └─────────────────────────────┘
```

At discharge, death, or Day 28 whichever is sooner

At 3 months

7. STUDY PROCEDURES

7.1 SCREENING PROCEDURES

It will be the responsibility of the local investigator(s) to identify eligible adult trauma patients with haemorrhagic shock and ongoing bleeding as soon as possible after the patient has arrived in the ED, using local transfusion triggers.

If patients are deemed to be eligible, consent for entry into the study will be sought (see *Section 9.5*).

Data will be collected on all adult trauma patients admitted to the ED with major blood loss throughout the recruitment period, who are screened for eligibility by the investigator(s).

A screening log will be completed once a week, which will record all patients considered for eligibility to the trial. The log will include age, gender, inclusion/exclusion criteria and other reasons for non-enrolment. The screening log will include patients approached but for whom consent was not obtained for the trial (with reasons). The screening log data will be reviewed at regular intervals.

7.2 RANDOMISATION PROCEDURES

Enrolled patients will be block randomized per centre to either the CCT or the VHA study arm. The randomised controlled trial will be unblinded.

Once a patient is determined eligible for the study and informed consent or agreement has been obtained, each subject will be enrolled as soon as possible and will be assigned a unique study identifier; this will be used throughout the subjects' participation in the study and will be documented on the enrolment log. This unique identifier will be alphanumeric, reflecting the study, the site and commencing at '001', ascending sequentially thereafter (i.e. iTACTIC_RLH_001 etc)

Randomisation will occur within 3 hours of injury and within one hour of admission.

24-hour on-site randomization will be performed by envelope opening, to allow for immediate allocation of subjects. An independent party, appointed by the Sponsor, will generate the randomization sequence and site envelopes centrally. These will be provided to each study site in a secure manner.

The site Investigator or designee will open a pre-sealed envelope containing the randomised treatment group allocation. Once randomised, the subject's pack details will be documented on the enrolment log.

7.3 SCHEDULE OF INTERVENTION

The following procedures will be conducted after arrival of the subject at the hospital:

7.3.1 Screening

- Assess eligibility (refer to inclusion/exclusion criteria)
- Check that written consent/agreement has been given to participate in the study in the form of a signed and witnessed informed consent form

- Medical and trauma history

- Physical examination

- Medical and treatment-related events prior to randomization, as well as surgical interventions

- All fluid/ transfusions and tranexamic acid given prior to randomization

- Resuscitate in accordance with the randomization sequence

7.3.2 Resuscitation

The following assessments will be conducted at baseline, after every 4th unit RBC during on-going resuscitation and until haemostasis:

- Physical examination (at baseline and haemostasis timepoints only)

- Blood sampling

- Haematology (baseline only)

- Blood chemistry (baseline only)

- Arterial blood tests (at baseline and haemostasis timepoints only)

- CCT

- VHA parameters in VHA arm

7.3.3 Hours 6 and 24 hours

The following assessments will be conducted at each specified time point after admission:

- Haematology (24 hours only)

- Arterial blood tests

- Blood chemistry (24 hours only)

- CCT

- VHA parameters in VHA arm

- Total blood products

- Total coagulation factor concentrates and Tranexamic acid

- Timings and total fluid volume

- Serious adverse events (SAE)

- Medical and treatment events, as well as surgical interventions

- Time of haemostasis

- Time of corrected coagulopathy

7.3.4 Day 0 to Day 28

The following assessments will be conducted daily, until 28 days post admission (inclusive) or upon discharge or death:

- Surgical treatment
- Thromboprophylaxis/prothrombotic medication
- Inotropes
- Episodes of bleeding
- Symptomatic thrombotic events
- Organ failure assessment (SOFA score) until discharge from ICU
- Serious adverse events (SAE)
- Death

7.3.5 Day 28 or upon hospital discharge

The following assessments will be recorded on day 28 or upon discharge from hospital, whichever occurs sooner.

- Days on mechanical ventilation
- Days on vasopressors
- Days on renal replacement therapy
- Total length of stay in the intensive care unit
- Total length of stay in the hospital
- Death
- Other SAEs
- Symptomatic venous thromboembolic events

Note - If the patient is discharged before Day 28, the patient will be examined for SAEs up to Day 28 at their Day 90 $\pm$ 5 days assessment.

7.3.6 Upon hospital discharge

The following assessments will be upon discharge from hospital, or within 5 days thereafter:

- QoL questionnaire (performed on hospital discharge or day 28, whichever comes first)
- First destination after discharge (home, rehabilitation facility, nursing home, other hospital, other)

7.3.7 Day 90

The following assessments will be conducted on day 90 $\pm$ 5 days:

- Mortality status
- QoL questionnaire

- Current disposition (home, rehabilitation facility/nursing home, other hospital, other)

7.4 PROCEDURES

7.4.1 Medical and trauma history

The medical and trauma history will be conducted at screening and should include (but not be limited to) date & estimated time of injury, injury description, abbreviated injury scale (AIS by body region), date and time of admission to hospital, subjects' medical history with an emphasis on the trauma, current medication, past medication and allergies. Known pregnancy, any pre-injury coagulopathy, use of anticoagulant medication (excluding aspirin) and reason for use will be specifically documented in the CRF. This will be ascertained as part of the subjects' initial clinical assessment by the trauma team and the investigator.

The known medical history must be documented in the subject's notes (the on-site source document) prior to randomised care and also recorded in the CRF. Any further medical history ascertained subsequent to the initial assessment will be derived from the subjects' notes during the assessment phase.

7.4.2 Physical examination

On-scene observations and observations made upon arrival at the ED and should include (but not limited to) age, weight, height, Glasgow Coma Scale (GCS), Heart Rate (HR), Systolic Blood Pressure (SBP), Glasgow Coma Score (GCS), Respiratory Rate (RR), Arterial Oxygen fraction-ratio (PaO_2/FiO_2 ratio), Oxygen Saturation (SaO_2), body temperature.

SBP will be recorded using a standard sphygmomanometer reading or by invasive arterial monitoring (where this has been inserted as part of routine clinical care). Pulse rate and SaO_2 will be measured by pulse oximetry or by arterial monitoring as above. Respiration rate will be assessed by observation as breaths per minute and a tympanic body temperature measure will be used, unless other methods (e.g. rectal or urinary bladder monitoring) are in place for continuous clinical monitoring. GCS will be recorded from the subject notes or assessed clinically.

7.4.3 Blood samples

During the first 24 hours, subjects will have a maximum of 20 mls of blood drawn per sampling time point (see *Section 12.4*) to determine the level of key blood components and functional coagulation status at the following time points:

- At hour 0 (within 10 minutes) immediately following study enrolment
- After every 4th unit RBC transfused until haemostasis (maximum 10 mls blood obtained at RBC time points)
- At haemostasis (within 30 minutes)
- At 6 hours post admission (within 30 minutes)
- At 24 $\pm$ 1 hours post admission

The maximum volume of 20 mls of blood sampled equates to approximately 0.5% of the total circulating blood volume. It is not anticipated that the study samples taken will have any adverse effects on clinical outcomes, also considering that eligible patients will be receiving blood transfusions during their acute phase of treatment.

7.4.4 Haematology

Standard haematology measures will comprise Haemoglobin levels (Hb) and Haematocrit (Hct). These will be determined at baseline and 24 hours.

In addition, White Blood Cells count (WBCs count) shall be conducted at baseline and at 24 hours.

7.4.5 Blood chemistry

Standard laboratory assays for blood chemistry shall be conducted to determine Bilirubin, Creatinine, Urea, These will be determined at baseline and 24 hours post admission.

7.4.6 Arterial blood tests

Arterial blood gases to determine pH, oxygen tension (PaO2), carbon dioxide tension (PaCO2), Base Excess, levels of Lactate and Ca^{2+}.will be taken:

- At hour 0 (within 10 minutes) immediately following study enrolment
- At haemostasis (within 30 minutes)
- At 6 hours post enrolment (within 30 minutes)
- At 24 $\pm$ 1 hours post enrolment

7.4.7 Conventional Coagulation Tests

Conventional Coagulation Tests (CCT) shall be conducted for all subjects in the CCT arm at each time point detailed in section 7.4.3 up to 24 hours.

The tests shall comprise Platelet Counts (PC), activated Partial Thromboplastin Time (aPTT), Prothrombin Time - International Normalized Ratio (PT/INR) and Clauss Fibrinogen assay.

Prothrombin ratio (PTr) and Clauss Fibrinogen shall be measured for all study subjects at each time point detailed in section 7.4.3 up to 24 hours. During active haemorrhage, samples will be taken for CCT analysis at baseline and after every 4 units of RBC until haemostasis. The results will be used to guide intervention provided any planned intervention based upon the previously analysed sample has been administered to the patient. If a planned intervention has not yet been administered, the sample will be taken and analysed (where resources allow) but will not be used to guide intervention. The first sample taken after an intervention is actually administered will be the next sample used to guide intervention based upon the protocol.

7.4.8 Viscoelastic Haemostatic Assays

Viscoelastic Haemostatic Assays (VHA) will be conducted for all subjects in the VHA arm at each time point detailed in section 7.4.3 up to 24 hours.

During active haemorrhage, samples will be taken for VHA analysis at baseline and after every 4 units of RBC until haemostasis. The results will be used to guide intervention provided any planned intervention based upon the previously analysed sample has been administered to the patient. If a planned intervention has not yet been administered, the sample will be taken and analysed (where resources allow) but will not be used to guide intervention. The first sample taken after an intervention

is actually administered will be the next sample used to guide intervention based upon the protocol.

According to pre-designation, each study centre will only conduct VHA using either Thromboelastography (TEG®) or Rotational Thromboelastometry (ROTEM®) to determine parameters:

- RapidTEG® - ACT, MA and Ly30; TEG® Functional Fibrinogen: MA
- ROTEM® - CT, CA5 and Li30 in ExTEM, and CA5 in FibTEM

7.4.9   Outcome Measures

SOFA score
For a full description please refer to *Section 12.2*

SOFA score will be registered until discharge from ICU.

Adverse Reactions
For a full description please refer to *Section 7.7*

Blood Products & Procoagulants
Timings, total number (and doses if appropriate) of different blood products and procoagulants administered both pre-hospital and after admission to the study centre, during resuscitation and after 6 and 24 hours shall be recorded including:

- RBC, FFP/Octaplas, Cryoprecipitate, platelets, whole blood and/or autologous RBC from cell salvage
- Coagulation factor concentrates (PCC, fibrinogen, rFVIIa)
- Tranexamic acid

Fluids
Timings (during first 24 hours only) and total volume of different fluids administred both pre-hospital and after admission to the study centre until 24 hours shall be recorded including crystalloids, colloids and hypertonic saline.

Thromboprophylaxis/prothrombotic medication
Type of medication administered, timings, dose and indication shall be recorded daily until day 28 with particular attention to duration of treatment (stop date).

Bleeding episodes
Qualfying episodes shall be defined by radiological evidence and/or clinical suspicion combined with transfusion requirement after initial haemostasis.

Ventilator-free days
Calculated by the subtracting the number of days spent on mechanical ventilation from 28.

Vasopressor days
Calculated as the total number of days spent on ionotropic drugs, including for instance noradrenaline, dobutamine, vasopressin.

Renal replacement therapy days
Calculated as the number of days spent on haemodialysis or haemofiltration.

ICU days
The total length of stay in the intensive care unit (ICU). If the patient is in the ICU at any time point during a day, this day will be considered an ICU day.

Length of Stay
Length of stay will be recorded in days, for the total number spent in ITU and in Hospital. If the patient is in the hospital at any time point during a day, this day will be considered a hospital day.

Surgical episodes
Description, timing, duration and reasons for all surgical episodes shall be recorded.

Thromboembolic events
Symptomatic venous thromboembolic events shall be recorded, as confirmed by radiology:

TYPE OF VENOUS THROMBOEMBOLISM	DIAGNOSIS
Deep venous thrombosis	Accepted methods of diagnosis include: • compression ultrasound • venography
Pulmonary embolism	Accepted methods of diagnosis include: • CT pulmonary angiogram (CTPA) • Ventilation-Perfusion scan (V/Q or Q scan as per local guidelines)

Other thromboembolic events such as myocardial infarction and/or stroke shall be identified by standard clinical diagnostic investigation(s).

Patient disposition
First destination after discharge and disposition at 90-day post admission shall be recorded as either home, rehabilitation facility, nursing home, other hospital or other.

Quality of Life
Subject quality of life shall be assessed using the EuroQoL EQ-5D™ questionnaire, a standardised instrument for use as a measure of health outcome. Quality of life assessment will be conducted in the study centre upon discharge of the subject from hospital and at 90 days post admission.

The in hospital (i.e. discharge) questionnaire will be conducted by research investigators with the patient where possible, but may also be completed with patients personal consultee if necessary. The questionnaire can be completed in less than five minutes. Where the subject has already left hospital, the questionnaire will be posted out with a return stamped addressed envelope. The questionnaire provides instructions for completion of the whole questionnaire, and will be accompanied by a cover note requesting return of the completed form within 5 days.

Patients who have not returned the questionnaire within two weeks of the initial request will be telephoned as a reminder to complete the questionnaire and may be asked to complete it over the phone if necessary. A maximum of three recorded

contact attempts will be made via phone and if these are unsuccessful, no further contact will be made and responses will be marked as not returned.

A further EuroQoL EQ-5D™ questionnaire shall be provided to assess subject quality of life at 90 + 5days post admission. Confirmation with the local (i.e. hospital care record system) and regional resources (i.e. NHS Health & Social Care Information Centre Spine Services) will ensure only surviving patients receive a questionnaire.

7.5 STUDY INTERVENTION

All participating centres currently manage critically bleeding trauma patients according to a standardized Massive Transfusion Protocol (MTP) aiming at a ratio of RBC 1: plasma 1: platelets 1 (1:1:1), typically administering plasma from the start of resuscitation and platelets immediately as they become available.

Corresponding and optimized algorithms based on VHA trigger parameters for the VHA arm and CCT results for the CCT arm respectively, have been developed and will be applied in the enrolled subjects.

The same blood products and procoagulants will be employed in both study arms, with existing standard practice in all participating centres being closely aligned to that of the CCT arm.

Enrolled patients will be block randomized per centre to either study arm:

- CCT: Haemostatic resuscitation, based on a MTP aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and CCT to guide further resuscitation with blood products and procoagulant factors.

- VHA: Haemostatic resuscitation, based on a MTP aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and VHA-guiding further resuscitation with blood products and procoagulant factors.

7.5.1 BLINDING

The trial is to be conducted in an unblinded, randomised controlled manner. It will be clearly evident to both the study site trauma team and its research team into which arm of the trial the subject has been randomised.

Where appropriate and possible, the blind will be maintained for staff involved in data analysis and interpretation.

7.5.2 STANDARD CARE

All participating centres currently resuscitate according to a 1:1:1 MTP [12].

Current use of additional diagnostics and therapy such as systematic approach according to ATLS principles, early imaging (e.g. X-rays, FAST, CT), activation criteria for MTP, surgical approach applying damage control principles when indicated, the availability and use of interventional radiology), will not be affected in either of the study groups.

All participating centres apply the same principles of care but variation does exist across centres. However the block randomization of subjects by centre will prevent the trial results from being influenced by any such differences.

An optimized initial MTP based on a 1:1:1 balanced transfusion will be implemented in all centres for approx. 2 months prior to initiation of the RCT and standardized as far as local routines and blood product availability allow.

Corresponding and optimized treatment algorithms based on CCT and VHA monitoring will be applied during the resuscitation of subjects enrolled to the CCT and VHA arms respectively.

7.5.3 INITIATION OF STUDY CARE

All participating centres will initiate the management of the study population according to local routines regardless of enrolment in the trial. Trial products will be given as an addition to the 1:1:1 baseline MTP:

1. Activation of MTP (according to local routines)

- Clinical signs of haemorrhagic shock and initiate first transfusion

2. Empiric resuscitation

- **1:1:1** - 1 RBC : 1 FFP/Octaplas : 1 Platelets
- **TXA** - 1g iv + 1g iv 8 hours infusion, if < 3 hours post injury.
  - If 1g administered prehospital, add 1g iv 8 hours infusion

7.5.4 RANDOMISED STUDY CARE (CCT ARM)

The clinical course of subjects randomised to the CCT arm will follow a treatment algorithm utilizing CCT results. The results from each blood sample will be acted upon as soon as they are available.

During active haemorrhage, samples will be taken for CCT analysis at baseline and after every 4 units of RBC until haemostasis. The results will be used to guide intervention provided any planned intervention based upon the previously analysed sample has been administered to the patient. If a planned intervention has not yet been administered, the sample will be taken and analysed (where resources allow) but will not be used to guide intervention. The first sample taken after an intervention is actually administered will be the next sample used to guide intervention based upon the protocol.

CCT arm Algorithm

FIBRINOGEN
If Fibrinogen <2g/L
Give additional 4g equivalent of fibrinogen
(As Cryoprecipitate or Concentrate)

PLATELETS
If Platelets <100 x10^9/L
Give 1 additional pool of platelets

PLASMA
If INR >1.2 **AND** Fibrinogen ≥2g/L
Give 4 additional units of plasma

7.5.5 RANDOMISED STUDY CARE (VHA ARM)

The clinical course of subjects randomised to the VHA arm will follow a treatment algorithm utilizing VHA results (see *Figure 3b*).

The results from each blood sample will be acted upon as soon as they are available. For the VHA arm, this implies acting upon the parameters as they are appearing, not waiting until the VHA trace is completed.

During active haemorrhage, samples will be taken for VHA analysis at baseline and after every 4 units of RBC until haemostasis. The results will be used to guide intervention provided any planned intervention based upon the previously analysed sample has been administered to the patient. If a planned intervention has not yet been administered, the sample will be taken and analysed (where resources allow) but will not be used to guide intervention. The first sample taken after an intervention is actually administered will be the next sample used to guide intervention based upon the protocol.

A total of 2287 patients were enrolled in the ACIT study [10] during the period 2008-2014. Analyses to define clinically relevant threshold values for VHA interventions were performed on a subset of 2015 patients whose functional coagulation status was recorded using ROTEM, and on a subset of 963 patients studied using TEG®.

Univariate and multivariate statistical modelling with receiver operating characteristic (ROC) curves were used in order to define test performance and identify TEG® parameters significantly associated with coagulopathy (INR>1.2, Fibrinogen < 1g/l, <1,5g/l and <2g/l) and clinical outcomes (i.e. transfusion requirements). Their corresponding threshold values were defined as the most sensitive and specific values using the Youden Index.

In the multivariate model Area Under the Curve (AUC) was calculated for both a multivariate continuous model, a multivariate categorical model and a univariate OR cut off model (when one of the significant values were positive according to cut off value defined by Youden Index).

The univariate and multivariate statistical analyses were performed with R Project for Statistical Computing. The multiple imputations and the rest of the statistical analyses were performed using SPSS Statistics 22. Statistical significance was defined as a p-value < 0.05.

VHA Algorithm RoTEM ®

FIBRINOGEN
If FIBTEM CA5 < 10mm
Give additional 4g equivalent of fibrinogen
(As Cryoprecipitate or Concentrate)

PLATELETS
If (EXTEM CA5 - FIBTEM CA5) < 30mm
Give 1 additional pool of platelets

PLASMA
If EXTEM CA5 ≥40mm **AND** EXTEM CT >80s
Give 4 additional units of plasma

TRANEXAMIC ACID
If EXTEM LI30 <85%
Give additional 1g IV bolus of tranexamic acid

VHA Algorithm rTEG ®

FIBRINOGEN
If FF-TEG MA < 20mm
Give additional 4g equivalent of fibrinogen
(As Cryoprecipitate or Concentrate)

PLATELETS
If (RAPID-TEG MA – FF-TEG MA) < 45mm
Give 1 additional pool of platelets

PLASMA
If RAPID-TEG MA > 65mm **AND** RAPID-TEG ACT >120
Give 4 additional units of plasma

TRANEXAMIC ACID
If LY30 >10%
Give additional 1g IV bolus of tranexamic acid

7.5.6   CESSATION OF STUDY CARE (HAEMOSTASIS)

For the purposes of this comparative study, the end of intervention shall be defined as the end of resuscitation for active bleeding (i.e. haemostasis).

Hemostasis shall be defined as the point 1 hour from the last administration of RBC and the treating clinician believes primary haemostasis has been achieved.

7.6 PROCEDURE FOR DATA COLLECTION

It will be the responsibility of the local researcher(s) to identify eligible adult trauma patients with haemorrhagic shock and ongoing bleeding as soon as possible after the patient has arrived in the ED of the study centre, using local transfusion triggers.

A daily screening log will be completed by research personnel at all participating centres, documenting the total number of adult trauma patients admitted to the ED with major blood loss throughout the recruitment period. Data will be collected for eligible patients who have not been recruited to the study and will be captured on a separate data sheet.

Once final eligibility is confirmed and consent is obtained, the adult trauma patient will be randomised into the study according to the procedures described in Section

7.4. Study subject data will be captured locally using a paper CRF, following local data security routines. Two persons at each centre provide validation of complete and accurate CRF data entry (one has to be a physician). CRF data are transferred and uploaded to a centralised study database whereupon study data integrity is reviewed weekly by the trial coordinating centre.

7.7 ADVERSE EVENTS REPORTING

Patients included in this trial have a high risk of morbidity and mortality, with either treatment being administered during a phase of critical bleeding and circulatory failure. Therefore, patients have a very high risk of experiencing several adverse events (AEs) and serious adverse events (SAEs).

The principles of ICH GCP require that both investigators and sponsors follow specific procedures when notifying and reporting adverse events or reactions in clinical trials. These procedures are described in this section of the protocol.

7.7.1 Definitions of Serious Adverse Events and Adverse Events

The definitions to be applied to SAEs and AEs recorded in this trial are given in Table 7a below. As this is a trial using blood products and prothrombotic agents, events of interest for safety reporting are those related to transfusion including specifically thromboembolic complications.

Table 7a: Definitions

Term	Definition
Adverse Event (AE)	Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product, and which does not necessarily have a causal relationship with this treatment.
Transfusion Related Adverse Reaction or Event	Any untoward and unintended response to a transfused blood component.
Serious Adverse Event (SAE) or Serious Transfusion related Adverse Reaction	Respectively any adverse event, adverse transfusion reaction or unexpected adverse transfusion reaction that: • results in death* • is life-threatening** • requires hospitalisation or prolongation of existing hospitalisation*** • results in persistent or significant disability or incapacity • Results in a congenital anomaly/birth defect • Other medically significant event
Unexpected Adverse Transfusion Reaction	An adverse reaction, the nature or severity of which is not consistent with the known reactions to transfusion of a blood component.

* Death due to the underlying disease or associated conditions will not be reported as an SAE.
**The term 'life-threatening' in the definition of 'serious' refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.
***Hospitalisation is defined as an inpatient admission, regardless of length of stay, even if the hospitalisation is a precautionary measure for continued observation. Hospitalisations for a pre-existing condition (including elective procedures that have not worsened) do not constitute an SAE.

- An ***unexpected SAE*** is defined as any event meeting the definition of an SAE above and that is not listed in the protocol as an "expected SAE not subject to expedited reporting" (see 7.7.2 and 7.7.3).

- An ***unexpected related SAE*** is defined as an unexpected SAE that is judged to be possibly, probably or definitely related to the transfusion policy being used in this hospital

7.7.2 Expected SAEs not subject to Expedited Reporting (expected occurrences)

Participants in this study are presenting with major blood loss following severe injury. Many of these patients will be expected to develop SAEs during the course of their hospital admission. All SAEs, expected or not, will be recorded on an SAE form. The following situations that fulfil the definition of an expected SAE (7.7.1) are not subject to expedited reporting by the site.

7.7.3 Expected SAEs which are Clinical outcome measures
- Deaths
- Bleeding
- Any element of thromboembolic and ischaemic events- (myocardial infarction, stroke, pulmonary embolus, DVT)
- Organ failure (single or multi-)
- Acute lung injury
- Respiratory compromise and need for ventilation and intubation

7.7.4 Expected SAEs which are not Clinical outcome measures
- Infection
- Congestive cardiac failure
- Respiratory complication:
  - Aspiration pneumonia
  - Pulmonary oedema
- Transient ischaemic attack
- Acute transfusion reactions (see section 12.5.1)
- Non-acute transfusion reactions (see section 12.5.2)

Note: Any event meeting the definition of an SAE and not listed above will be treated as an "unexpected SAE".

7.7.5 Notification and Reporting of Serious Adverse Events

Serious Adverse Event (SAEs) that are considered to be 'related' and 'unexpected' are to be reported to the sponsor within 24 hours of learning of the event and to the Main REC within 15 days in line with the required timeframe.

7.7.6 Urgent Safety Measures

The CI may take urgent safety measures to ensure the safety and protection of the clinical trial subjects from any immediate hazard to their health and safety. The measures should be taken immediately. In this instance, the approval of the REC prior to implementing these safety measures is not required. However, it is the responsibility

of the CI to inform the sponsor and Main Research Ethics Committee (via telephone) of this event immediately.

The CI has an obligation to inform both the Main REC in writing within 3 days, in the form of a substantial amendment. The sponsor (Joint Research Management Office [JRMO]) must be sent a copy of the correspondence with regards to this matter.

7.7.7 Investigator Responsibilities

The Chief Investigator has overall responsibility for the conduct of the study. As this is a multi-site study, the Principal Investigator has responsibility for the research at their local site and is responsible for informing the Sponsor of all reportable SAEs that occur at their site following the guidelines below.

- The Sponsor should be notified within 24 hours of the Principal Investigator becoming aware of the SAEs and outcomes listed in section 7.3. Investigators should notify the Sponsor of all such events occurring up to study Day 28.
- The relevant forms must be completed by the Investigator (the consultant named on the delegation of responsibilities log who is responsible for the patient's care). In the absence of the Investigator, the form should be completed and signed by a member of the site trial team and faxed or emailed. The responsible Investigator should subsequently check, annotate and sign the form and re-fax/email to the Sponsor as soon as possible. The initial report must be followed by detailed written reports as appropriate.
- The investigator must follow-up all reported SAEs and clinical outcomes which require expedited reporting (whether they are expected or not) until resolution or the event is considered stable.
- Investigator must supply the Sponsor, REC and relevant NHS Trust R&D with any supplementary information they request.

7.7.8 Annual Safety Reporting

The CI will send the Annual Progress Report to the main REC using the NRES template (the anniversary date is the date on the MREC "favourable opinion" letter from the MREC) and to the sponsor.

7.7.9 Statutory Reporting

Hospital staff remain responsible for reporting all transfusion-related adverse events to SHOT/SABRE according to standard procedures, as required under the regulations of the EU Blood Directive. Staff at the institution are also responsible for notifying their local R&D department of SAEs (as per the institutions standard local procedure).

<div style="border: 3px solid red; background-color: #999999; padding: 20px; text-align: center;">

SAE REPORTING

Within 24 hours of becoming aware of a reportable SAE please fax a
completed SAE form to the Sponsor on:

+44 20 7882 7276

Or E-mail information to: **research.safety@bartshealth.nhs.uk**

</div>

7.8   INVESTIGATORS ASSESSMENT

7.8.1   Seriousness

The Chief/Principal Investigator responsible for the care of the subject, or in his
absence an authorised medic within the research team, is responsible for assessing
whether the event is serious according to the definitions given in *Section 7.7.1.*

7.8.2   Causality

The Investigator must assess the causality of all serious adverse events/reactions in
relation to the trial treatment according to the definition given. If the SAE is assessed
as having a reasonable causal relationship, then it is defined as a SAR.

7.8.3   Definitions of Causality

Relationship	Description
Unrelated	There is no evidence of any causal relationship
Unlikely	There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a reasonable time after administration of the trial drug or intervention). There is another reasonable explanation for the event (e.g. the patient's clinical condition, other concomitant treatment).
Possible	There is some evidence to suggest a causal relationship (e.g. because the event occurs within a reasonable time after administration of the trial drug or intervention). However, the influence of other factors may have contributed to the event (e.g. the patient's clinical condition, other concomitant treatments).
Probable	The evidence is clearly in favor of attributing the adverse reaction to the trial drug or intervention
Definitely	There is conclusive evidence beyond reasonable doubt attributing the adverse reaction to the trial drug or intervention.
Not assessable	There is insufficient or incomplete evidence to make a clinical judgment of the causal relationship.

7.8.4 Expectedness

The investigator must assess the expectedness of all SARs according to the definition given. If the SAR is unexpected, then it is a SUSAR.

7.9 SAFETY ANALYSIS

A pre-defined interim analysis will be performed after the enrolment of 100 patients, including an assessment of recruitment logistics with the possibility to revise the planned sample size.

A Data Safety Monitoring Board (DSMB) will review all data on outcome of the patients in the respective treatment arms. The DSMB will focus on adherence to protocol, and present pre-specified criteria that need to be fulfilled with regard to safety of the patients for the study to continue.

7.10 SUBJECT WITHDRAWAL

Every reasonable effort will be made to maintain protocol compliance and to retain patient participation in the study, consistent with the provisions of informed consent and good clinical practice. The following are potential reasons why a patient may be withdrawn from the study:

1. Withdrawal of consent/agreement: the patient, the patient's personal consultee, independent physician, or designated individual who had provided initial consent/agreement to enter the study may withdraw consent/agreement at any time throughout the duration of the trial, without prejudice to future medical care and treatment.

2. Retrospective exclusion: If a patient is deemed to not meet one or more of the inclusion/exclusion criteria in retrospect they will be withdrawn from the study.

3. Major protocol deviation from the study design by the subject, observed or suspected by the investigator.

4. Administrative: the sponsor or monitoring committees decide to terminate or discontinue the study.

5. The subject's health would be jeopardised by continued participation and is withdrawn at the discretion of the investigator.

The study withdrawal form will be completed for these patients and a reason for withdrawal captured. All subject's withdrawn from the study will be managed in accordance with the hospital's standard procedures.

7.11 DATA COLLECTION AND FOLLOW-UP FOR WITHDRAWN SUBJECTS

Patients who withdraw from the study after randomisation should be followed for safety by conducting safety assessments through to the end of day 28. If a patient who withdraws has an ongoing SAE every effort must be made to follow such events until satisfactory resolution is obtained or until further follow-up is no longer warranted.

7.12 SUBJECT REPLACEMENT

Subjects who withdraw from the study will be replaced.

SCHEDULE OF INTERVENTION (in Diagrammatic Format)

ASSESSMENT	SCREENING & RANDOMISATION	RESUSCITATION (Every 4U RBC)	HAEMOSTASIS (1hr after last RBC)	6 HRS	24 HRS	UNTIL DAY 28 (Daily)	DISCHARGE	DAY 90
Eligibility	✕							
Informed Consent	✕							
Medical History	✕							
Physical Exam	✕	✕	✕	✕	✕			
Prior Surgery & Treatment	✕							
Blood Sample	✕	✕	✕	✕	✕			
Haematology	✕				✕			
Blood chemistry	✕				✕			
Arterial Blood Tests	✕		✕	✕	✕			
Conventional Coagulation Tests (CCT)	✕	✕	✕	✕	✕			
Visco Haemostatic Assays (VHA)	✕	✕	✕	✕	✕			
Total Blood, Coag Factor, Fluid & TXA	✕	✕	✕	✕	✕			
SOFA	✕				✕	end ICU	✕	
SAEs	✕	✕	✕	✕	✕	✕	✕	
Mortality				✕	✕	✕		✕
Ventiliator-free days						✕	✕	
Vasopressors days						✕	✕	
Renal Replacement Therapy days						✕	✕	
ICU days						✕	✕	
Hospital days						✕	✕	

Surgical episodes						✕	✕	
Thromboembolic events						✕	✕	
First destination							✕	
Quality of Life							✕	✕
Current disposition								✕

7.13 END OF STUDY DEFINITION

The study will be considered closed when all surviving Subjects complete in-hospital safety and outcomes monitoring. This includes: safety measures of serious adverse reaction rate within 28 days, total hospital stay, total critical care stay, 28-day ventilator free days, and 28-day mortality.

8 STATISTICAL CONSIDERATIONS

8.1 SAMPLE SIZE

The planned sample size for this study is 392 patients for which MTP is activated and transfusions initiated, 196 in each study arm.

Based upon legacy registry data from the Partners, approximately 28% of patients will need massive transfusion or die. This figure decreases to an overall proportion of 15% in the VHA group (i.e. using VHA guided strategy). With a power of 80% and a two-sided alpha of 0.05, 170 patients per group are required. Assuming a drop-out rate of 15% 196 patients are needed per group.

8.2 METHOD OF ANALYSIS

Subject characteristics
Continuous patient characteristics will be described as means with standard deviation or median, with interquartile range according to normal distribution. Normality will be checked using the histograms and Kolmogorov-Smirnoff test. Categorical patient characteristics will be described as number of patients and percentages.

Differences between centres will be explored and if detected, all analyses will also be corrected for centre using either a logistic regression or linear regression.

Endpoints
The primary endpoint of massive transfusion and death will be assessed by difference in proportion, using the Chi-square test or Fisher exact test as appropriate. Absolute risk reductions and relative risk reductions by VHA-guided therapy will be calculated. A two-sided p-value<0.05 will be considered significant.

Differences in secondary endpoints will be assessed by difference in means and tested using the Students-t test, or difference in median and tested using the Mann-Whitney U test as appropriate.

Calculating the area under the curve will assess the duration of and severity of coagulopathy until haemostasis. Differences between the two treatment arms will then be examined using Students t-test. Both ROTEM®-guided and TEG®-guided therapy together (i.e. VHA arm) will be compared with the CCT arm, as well as separate analyses for ROTEM®-guided and TEG®-guided therapy alone in regard the primary endpoints and correction of coagulopathy.

All analyses will be based on an intention to treat analysis, however a per-protocol analysis and a sensitivity analysis will also be performed for the primary endpoint. The following patients will be excluded from the per protocol analysis:

- Patients who do not have at least one ROTEM®/TEG®/CCT test performed
- Patients who die within 60 minutes after baseline blood sampling
- Patients who achieve haemostasis within 60 minutes of baseline sampling.

Subgroup analyses

The following patient subgroups will also be analysed separately:

- Patients with severe traumatic brain injury (defined as brain abbreviated injury score ≥4)
- Patients without severe traumatic brain injury (brain abbreviated injury score <4)
- Patients with known pre-existing coagulopathy
- Prior oral anticoagulant therapy except for aspirin

Integrated cost-effectiveness analysis

A cost-effectiveness analysis will be conducted to assess the costs and effects of VHA-guided therapy versus those of optimised empiric treatment. A model will be developed which will be structured around the key clinical time points and events in the early management pathway of bleeding trauma patients, for example discrete time periods modelled might include 0-3 hours post presentation, 3-6 hours, 6-12 hours and 12-24 hours with outcomes at the end of each period comprising: patient alive and free of massive transfusion, patient alive and massive transfusion ongoing, and patient deceased.

For each country individually, data from the CCT arm of the trial on numbers of patients experiencing the outcomes at the end of each period (together with the treatments (and their associated costs) received by patients in each time period) will be used to populate the model. Country-specific trial data (supplemented with trauma registry data) on survival and costs from 24 hours to 28 days (plus HRQoL at 28 days) will be added, and for patients still alive at 28 days, longer-term quality of life, life expectancy, and costs will be modelled using a combination of data from the trauma registry and the published literature).

In an identically structured VHA arm of the model, estimates of the trial's overall treatment effect (relative risk reduction) with VHA guided therapy will be used to adjust the outcomes in the CCT arm of the model for each country, so as to estimate the potential additional proportions of patients alive and free from massive transfusion at 24 hours with VHA testing.

The additional costs associated with VHA will be added to this arm of the model, together with the costs of treatment received by VHA trial patients in each of the discrete time periods to 24 hours. As per the CCT arm, country-specific trial data

(supplemented with trauma registry data) on survival and costs from 24 hours to 28 days (plus HRQoL at 28 days) will be added, and for patients still alive at 28 days, longer-term quality of life, life expectancy, and costs will be modelled using a combination of data from the trauma registry and the published literature).

The two treatment policies will be compared in terms of their estimated costs and effects (quality adjusted life years (QALYs): calculated by combining survival and HRQoL data) and incremental analyses will be performed. If VHA-guided therapy is more effective but also more costly than empirical treatment then the incremental cost-effectiveness ratio (ICER) will be calculated. The ICER is calculated by dividing the difference in costs between VHA and empirically guided therapy by the difference in effects (QALYs) and gives the additional cost of generating one additional unit of outcome (here a QALY).

So as to account for the uncertainty in the model input data, parameters will be entered as distributions rather than point estimates. Probabilistic sensitivity analysis will be used to take repeated random draws from all distributions simultaneously, each time recalculating the model's results for a total of 2000 times. The uncertainty will be summarised on the cost-effectiveness plane and using cost-effectiveness acceptability curves. For each country the modelling exercise should provide an estimate of the probability that VHA-guided therapy is likely to be cost-effective when compared with optimised empiric treatment.

9 ETHICS

9.1 SAFETY CONSIDERATIONS

Conducting clinical studies in trauma is challenging, with important safety considerations and needs concerning the priority for delivering life-saving patient care, whilst achieving the robust enrolment of subjects in the emergency setting.

This multicentre study will be achieved by employing a flexible trial protocol that accommodates variance in practice across sites and meets resource demands such that:

- The study will be conducted by dedicated research personnel, without obligations to the actual treatment of the subject, thereby ensuring both focused patient care and compliance to the study protocol

- Comprehensive screening and the conduct of study procedures will be achieved by the availability of multiple skilled research personnel, recruiting subjects presenting *in extremis* and often out of normal working hours (i.e. throughout the night).

9.2 RISKS

All parts of the study will be carried out to avoid patient risk and minimize discomfort at all times. At no time will patient care be compromised or delayed for the purposes of the study.

The study comprises a VHA arm that utilises a patient-matched treatment algorithm developed from the analysis of data from over 2,000 trauma patients describing haemostatic impact of different types of trauma-induced coagulaopthy and therapeutic interventions with blood products and pro-coagulants. The algorithms aim

to normalize haemostatic competence, as evaluated by functional haemostatic assays such as TEG® and ROTEM®, since all published evidence to date suggest that normal haemostatic competence in bleeding trauma patients is associated with improved outcome.

This is a randomised controlled trial in which all subjects regardless of randomisation will initially receive care encompassing a MTP aiming for a 1:1:1 ratio of RBC: plasma: platelets, according to the best currently available evidence [12]. Half of the patients (Intervention group) will be allocated to receive patient-matched VHA algorithm-led resuscitation in addition to the empiric MTP. The other participants (CCT group) will have their resuscitation adjusted in response to standard clinical and laboratory results (CCT).

There is a clear rationale and requirement for sequential blood sampling of study subjects during their acute phase of clinical care within the ED. The status and response of the patient's functional coagulation during resuscitation is a dynamic process and the full picture will not be apparent on a single baseline blood draw. Many trauma patients exhibit a coagulopathic state either at admission or in the later stages of the body's response to injury or treatment itself. How these changes manifest is poorly described, but would be defined by this protocol. This would have major implications for the future diagnosis and treatment of coagulopathy.

As most major trauma patients have an arterial or central line placed, most blood draws are not painful to the patient. Whenever possible the investigators will coordinate study blood draws with those of clinical need, to minimise disturbing the patient and the number of needle-sticks. The risks of blood sampling are limited to some potential bruising at the site of venepuncture, and discomfort to needle puncture (where no arterial line is already in place).

All serious adverse events associated with the study will be reviewed as they occur (see *Section 7.7*). Additionally, a pre-defined interim analysis will be performed after the enrolment of 100 patients in which all safety data of the patients in the respective treatment arms will be reviewed by a DSMB.

Participation in research may involve some degree of loss of privacy. However this risk will be minimized by the data protection methodology (see *Section 10*), although the study does not include any tests that might subsequently result in significant personal, financial or social risk to research subjects. Every effort will be made to ensure that the study data is secured and patients' privacy remains protected.

9.3 BENEFIT TO THE PATIENT

There may be a direct benefit to those subjects receiving the Intervention.

There is no incentive for participation in the study.

9.4 BENEFIT TO SOCIETY

Trauma remains the leading cause of death and disability in patients under 45 years of age. Trauma patients tend to be young, active members of society, often with good jobs and young families to support. The outcome of trauma patients is determined in the first few hours following injury. Although the study may not carry a direct benefit to all its subjects, a societal benefit lies in the expected results of the trial that will

deliver evidence-based guidelines for the identification and management of coagulopathic bleeding in the trauma population.

9.5 PATIENT ENROLMENT

Eligible subjects will be enrolled at specialist trauma-receiving hospitals located in Amsterdam, Cologne, Copenhagen, London, Oslo and Oxford. Each study centre shall submit ethical application to their respective ethics committees for research on human subjects.

9.5.1 INFORMED CONSENT PROCEDURES

Most, but potentially not all, subjects will be incapacitated at the time of eligibility (critical injury, mechanical ventilation, sedation), such that the Mental Capacity Act (England; 2005) and Declaration of Helsinki (World Medical Association; 2013) provides guidance.

Patients will be recruited within 3 hours of their injury and within 1 hour of admission to the ED of the study site. This is at a particularly stressful time for relatives and families, an important consideration when the intervention under investigation is time sensitive. This study requires that the intervention be given rapidly, thereby necessitating that eligible patients are consented very soon after hospital admission. As injury is an unexpected event, it is uncommon that relatives are present at the time of hospital admission.

As stipulated by International Conference on Harmonisation guidelines for Good Clinical Practice the subject and/or their Personal Consultee (PC) (e.g. next of kin) should be given ample time to consider giving their consent/agreement for the study. It is felt that 24 hours gives sufficient time for the patient and/or PC to consider participation within the study and give informed consent/agreement. However, the need for urgent treatment in this trial means that the implementation of the research cannot be delayed and that it would be inappropriate to delay treatment until fully informed consent/agreement can be obtained from the patient, relative or other PC. Patients who are incapable of giving consent in emergency situations are an established exception to the general rule of informed consent in clinical trials.

As the timeframe required for subject or PC consent/agreement is not compatible with the time sensitivity of this trial, several approaches to obtaining informed consent/agreement will be used, all of which are consistent with the Mental Capacity Act (England; 2005) and the Declaration of Helsinki (2013):

Declaration for initial enrolment in the trial will be sought from a Nominated Consultee (NC), in the form of independent clinicians (e.g. trauma team leader) who are familiar with this study's consenting process and are present at the trauma call. Senior Emergency Department clinicians acting as NC will receive information about the study by a combination of an oral presentation and a written information sheet and have the opportunity to ask questions and discuss the study with investigators prior to study enrolment.

If PCs are present, bearing in mind the clinical situation and their level of distress, they will be provided with brief information about the trial either verbally or in writing. Specifically, the investigator will explain to the PC that the patient will receive the usual emergency treatments for traumatic haemorrhage but that in addition to these,

the patient has been enrolled in a research study that aims to improve the outcome of patients with this condition.

It will be explained that the study is being conducted to see whether using a diagnostic test to guide personalised transfusion therapy will improve patients' outcome by stemming bleeding more quickly. The relative will be informed that the patient will be treated by transfusion of the same blood products and clotting agents, initially by a massive transfusion protocol aiming to deliver blood products in fixed ratio and subsequently in a pre-determined manner according to test results obtained during the bleeding patient's treatment, either conventional clotting tests (CCT arm) or more sophisticated coagulation monitors (VHA arm). The investigator will explain that whilst we hope that use of the diagnostic test will improve outcome after trauma haemorrhage, we cannot presently be sure of this.

If the PC objects their wishes will be respected. If no PC is present, two doctors (one independent of the trial) will consider the patient's eligibility criteria and any known views of the patient about trial participation. Together they will decide whether or not to enrol the patient into the trial.

We do not propose to include a telephone contact with relatives/personal consultees in order to minimise stress and anxiety at a difficult time.

If and when subjects regain the physical and mental capacity to give consent, information will be provided to them and written informed consent will be sought for continuation in the trial. If a patient or representative declines to give consent/agreement for continuation at this stage, his/her wishes will be respected. For any patient who was included but did not regain full capacity, agreement will be sought from a relative or other appropriate representative for continuation of the trial. In this case, an attempt will be made by the investigator to discuss the trial with the PC during the daily visit for data collection if they are present and it is deemed an appropriate time for the discussion to take place. These attempts will continue until PC or subject consent/agreement is obtained. All interactions and attempts at contact with the PC and/or subject will be documented in a study consent log.

Patients who die during the follow up period or do not regain mental capacity, will be included in the study based on the advice provided by the Personal Consultee and/or nominated consultee. In cases where the subject dies before we have had the opportunity to discuss the trial and obtain consent/agreement from the patient or the Personal Consultee, the patient will remain in the trial based on the signed declaration obtained by the Trauma Team Leader (nominated consultee) and we will not attempt future telephone or written contact with relatives/Personal Consultee in order to minimise stress and anxiety associated with the unexpected and traumatic death of their relative / next of kin. Should an investigator have had the opportunity to introduce themselves and discuss the trial with the PC prior to the subject's death but written agreement has not yet been obtained, then we will make a maximum of three further attempts (by any combination of telephone, e-mail or letter) as deemed appropriate in each individual case to contact the PC and obtain written agreement. If after these further attempts, the PC has either not been contactable or has not returned written agreement, then the subject shall remain in the trial based on the NC declaration. If the PC objects to the subject remaining in the study at this stage then their wishes will be respected.

In summary, we believe these approaches are justified under the conditions of the Mental Capacity Act (England; 2005) and Declaration of Helsinki (World Medical Association; 2013) for the following reasons:

- The urgent/emergency nature of the intervention

- The proposed recruiting centre has used this consenting procedure for previous randomised controlled trials in trauma (MP4OX Ph2b - EudraCT: 2010-023129-39; Cryostat Ph2a – ISRCTN55509212) and the ongoing ACIT-2 observational study (REC ref: 07Q0603/29) that has successfully recruited more than 1300 patients to date.

Prior to any study related activities and subsequently for continuation when the subject is capable or from a relative or representative, two copies of the Informed Consent/agreement Form approved by the Research Ethics Committee must be signed and dated. One original copy must be retained by the site in its study file, together with any subsequent approved amended versions. The other original must be given to the subject for his or her own records.

9.5.2 REMOVAL OF PATIENTS FROM THE STUDY

The patient, the patient's personal consultee, independent physician, or designated individual who had provided initial consent or approval to enter the study may withdraw consent/agreement at any time throughout the duration of the trial, without prejudice to future medical care and treatment of the patient.

10 DATA HANDLING AND RECORD KEEPING

10.1 CONFIDENTIALITY

The Investigator has responsibility to ensure patient anonymity is protected and maintained. They will also ensure their identities are protected from any unauthorised parties. Information regarding study patients will be kept confidential and managed in accordance with the Data Protection Act, NHS Caldicott Guardian, The Research Governance Framework for Health and Social Care and Research Ethics Committee Approval.

The Investigator as well as the study team will adhere to these parameters to ensure the subject's identity is protected at every stage of participation within the study. To ensure this is done accordingly, each patient, at time of consent will be allocated a unique screening number by either the PI or a member of the study team before undergoing any screening procedures. The subject's initials (the first letter of their first name and the first letter of their last name) will be used as a means of pseudo-anoymising parameters. This information will be kept on a screening log, and updated accordingly throughout the study. Once the patient has completed screening procedures and is enrolled onto the study, they will be allocated a unique randomisation number by the investigator (see *Section 7.2*).

Subject identifiable information (name, date of birth, hospital number) will be recorded for the purposes of consent and data collection including AEs and SAEs (hardcopy Case Report Form). In addition, contact information for the subject (address, telephone number and General Practitioner Details) will be recorded in the consent log in the event an investigator may need to contact the subject or their GP

with regards to the trial. Access to all identifiable information will be limited to the study investigators.

If any subject information needs to be sent to a third party (including correspondence/communication to central laboratories, CROs, sponsor) the PI and the study team will adhere to patient pseudo-anonymous parameters. This includes the patient initials, date of birth, gender as well as the unique study ID/randomisation number. Any information that is to be collected by these third parties will utilise these coded details for any relevant documents as well as maintaining databases.

All Investigators agree that all information communicated by the sponsor is the exclusive property of the sponsor and will ensure that the same shall be kept strictly confidential or any other person connected with the work and shall not be disclosed to any third party without the prior written consent of the sponsor.

All rights and interests worldwide in any inventions, know-how or other intellectual or industrial property rights which arise during the course of and/or as a result of the clinical study which is the subject of the protocol or which otherwise arise from the information or materials supplied under this agreement, shall be assigned to, vest in and remain the property of the sponsor.

10.2 STUDY DOCUMENTS

- A signed protocol and any subsequent amendments
- Current Summary of Product Characteristics/ Investigator's Brochure
- Sponsor Self-Monitoring template for the trial team to complete on a regular basis as detailed by the Monitoring section
- Current/Superseded Patient Information Sheets
- Current/Superseded Consent Forms
- Indemnity documentation from sponsor
- Conditions of Sponsorship from sponsor
- Conditional/Final R&D Approval
- Signed site agreement
- Ethics//approvals/correspondence
- CVs of CI and site staff
- UK regulations (GCP) course certificate of each of trial team
- Laboratory accreditation letter, certification and normal ranges for all laboratories to be utilised in the study
- Delegation log
- Staff training log
- Site signature log
- Patient identification log
- Screening log
- Enrolment log
- Monitoring visit log
- Protocol training log
- Correspondence relating to the trial
- Communication Plan between the CI/PI and members of the study team
- SAR reporting plan for the study

10.3 CASE REPORT FORM

Data collection for this study will be accomplished using a paper case report form (CRF) to capture data prospectively and transferred to an electronic data capture system. CRFs are required and will be completed for each randomized subject. It is the Investigator's responsibility to ensure the accuracy, completeness and timeliness of the data reported on the subjects CRF. CRFs will be completed in a timely fashion to support the study timelines. Source documentation supporting the CRF data will indicate the subject's participation in the study and document the dates and details of informed consent/agreement and study procedures. Data collected on the CRF will be verified against the source documentation.

A Summary of Data Capture for the CRF is shown below:

- Eligibility/exclusion criteria checklist
- Informed consent/agreement including dates
- Demographics (including age, gender & hospital number)
- Date of screening
- Randomisation code
- Medical history (including pregnancy, pre-injury anticoagulant therapy or coagulopathy)
- Physical examination (including weight, vital signs & injury severity)
- Blood products and fluids administered over first 24 hours
- Conventional laboratory & VHA test results
- Surgical procedures (including duration)
- Thromboprophylactic medication
- SAE (see *Section 7.7*)
- Mortality (including time to death)
- SOFA score from admission to day 28 or discharge (see *Section 12.2*)
- Outcomes at discharge or day 28 (including total length of hospital stay, critical care stay, renal replacement therapy & ventilator-free days)
- 90-day mortality status

10.4 IDENITIFCATION OF SOURCE DATA

Source data includes all information in original records and certified copies of original records of clinical findings, observations or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certified copies).

The following items are defined as source data:
- Subject medical notes including prescription and observation charts.
- Barts Health NHS (Royal London Hospital site) electronic Care Records Service for access to clinical laboratory test results, radiology general practitioner or subject contact information.
- Subject monitoring equipment (vital signs).
- NHS Spine database for confirmation of 90 day mortality status.
- Correspondence (telephone or writing) with Subject.

Data such as weight, vital signs, heart rate, temperature, pregnancy test will be recorded in subject notes or on a study specific source data sheet. Where the CRF is used as source document for this trial, the data to which this applies will be documented in a File Note.

10.5 RECORD RETENTION AND ARCHIVING

It is the responsibility of the Chief Investigator (CI) to maintain adequate records for the study including completed CRFs, signed Informed consent/agreement documents, drug disposition records and all correspondence with the REC and the sponsor.

The CI must make study data accessible to the monitor and other authorised representatives of the Sponsor upon request. A file for each subject must be maintained that includes the signed Informed Consent/agreement form and the Investigator's copies of all source documentation related to that subject. The Investigator must ensure the reliability and availability of source documents from which the information on the CRF was derived.

All records are to be retained in a secure location for a minimum period of 20 years after the study has completed, as per the Research Governance Framework and Trust Policy. For trials involving BHT patients, undertaken by Trust staff, or sponsored by BHT or QMUL, the approved repository for long-term storage of local records is the Trust Modern Records Centre, which is based at 9 Prescot Street.

10.6 COMPLIANCE

The CI will ensure that the trial is conducted in compliance with the principles of the Declaration of Helsinki (2013), Research Governance Framework for Health & Social Care (2005), Principles of ICH-GCP, European Commission Directives 2001/20/EC and 2005/28/EC with the implementation in national legislation in the UK by Statutory Instrument 2004/1031 and any subsequent amendments, Trust and Research Office policies and procedures and any subsequent amendments.

10.7 CLINICAL GOVERNANCE ISSUES

10.7.1 Ethical considerations

This protocol and any subsequent amendments, along with any accompanying material provided to the subject in addition to any advertising material will be submitted by the Investigator to an Independent Research Ethics Committee. Written Approval from the Committee will be obtained and subsequently submitted to the JRMO to obtain Final R&D approval.

Verification of the Ethics Committee's unconditional approval of the protocol, subject information sheet and informed consent document will be transmitted to the sponsor prior to shipment of clinical supplies.

The written, unconditional approval from the Ethics Committee must refer to the study by exact protocol title and number, identify the documents reviewed and state the date of review. Any amendment to the protocol must be approved in the same way.

The ethics committee must be informed by the investigators of all subsequent protocol amendments and of serious or unexpected adverse experiences occurring during the study, which are likely to affect the safety of the subjects or the conduct of the study.

10.7.2 Regulatory Approval

The sponsor will be responsible for obtaining all relevant approvals to conduct the study, in accordance with any applicable requirements, prior to a site initiating the study and prior to any subsequent amendments.

10.7.3 Amendments

The study will be conducted according to this protocol. Any changes in procedure can only be implemented on completion of an amendment, the only exception to this will be if it is necessary to make a change due to urgent safety measures to protect the safety, rights or welfare of subjects.

Protocol amendments must be made only with the prior approval of the sponsor. Amendments will be classified as non-substantial or substantial by the sponsor.

In accordance with the Medicines for Human Use (Clinical Trials) Regulations (2004), non-substantial amendments can be made at any time during the trial with the prior approval of the sponsor. These will be documented and recorded as relevant.

For a substantial amendment to the protocol or supporting documents the sponsor will obtain approval as relevant from the REC.

The substantial amendments will also be notified to the JRMO.

10.7.4 Subject Compensation for Adverse Effects on Health

The sponsor will adhere to local regulations regarding Clinical Trial Compensation Guidelines to subjects whose health is adversely affected by taking part in the study.

11 QUALITY CONTROL AND QUALITY ASSURANCE

11.1 SUMMARY MONITORING PLAN

The site Clinical Trials Coordinator will perform regular monitoring of trial documentation and CRFs. During the set-up visit investigators will be given all relevant documentation and training in order for them to participate safely and effectively in the trial. The first monitoring visit will take place after the first subject is randomized into the trial. The monitoring plan will include 100% monitoring of consent/agreement forms and source data verification on a proportion of CRFs (including 100% verification of the data collected from the first 10 patients recruited). Investigators/institutions are required to provide direct access to source data/documents for trial-related monitoring, audits, ethics committee review and regulatory inspection.

11.2 AUDIT AND INSPECTION

For the purpose of compliance with Good Clinical Practice (GCP) and Regulatory Agency Guidelines it may be necessary for the sponsor or a Drug Regulatory Agency to conduct a site audit. This may occur at any time from the start to after conclusion of the study. A study may be identified for audit by any method listed below:

- A project may be identified via the risk assessment process.

- An individual investigator or department may request an audit.

- A project may be identified via an allegation of research misconduct or fraud or a suspected breach of regulations.

- Projects may be selected at random. The Department of Health states that Trusts should be auditing a minimum of 10% of all research projects.

- Projects may be randomly selected for audit by an external organisation.

Internal audits will be conducted by a sponsor's representative.

When an Investigator signs the protocol, he/she agrees to allow the Drug Regulatory Agency or the sponsor auditors to inspect his/her study records. Furthermore, if an Investigator refuses an inspection, data from that centre will not be accepted in support of a New Drug Registration and/or Application.

11.3 SERIOUS BREACHES IN GCP OR TRIAL PROTOCOL

The sponsor of the Clinical Trial is responsible for notifying the licensing authority in writing of any serious breach of:

- The conditions and principles of GCP in connection with that trial; or

- The protocol relating to the trial, as amended from time to time in accordance with regulations 22 to 25, within 7 days of becoming aware of that breach.

For the purposes of this regulation, a 'serious breach', is a breach which is likely to effect to a significant degree:

- The safety or physical or mental integrity of the subjects of the trials; or

- The scientific value of the trial.

The CI is responsible for reporting any serious breaches to the sponsor (JRMO) **within 24 hours**.

11.4 NON-COMPLIANCE

Non-compliance is a noted systematic lack of both the CI and the study staff adhering to SOPs/protocol/ICH-GCP and UK regulations, which leads to prolonged collection of deviations, breaches or suspected fraud.

Instances of non-compliance may be captured from a variety of different sources including monitoring visits, CRFs, communications and updates. The sponsor will maintain a log of the non-compliances to ascertain if there are any trends developing which to be escalated. The sponsor will assess the non-compliances and action a

timeframe in which they need to be dealt with. Each action will be given a different timeframe dependent on the severity. If the actions are not dealt with accordingly, the JRMO will agree an appropriate action, including an on-site audit.

11.5 SPONSORS TERMINATION OF STUDY

The sponsor reserves the right to discontinue the clinical study at any time for medical or administrative reasons. When feasible, a 30-day written notification will be tendered.

11.6 INDEMNITY AND INSURANCE

The sponsor will provide indemnity in accordance with the agreement with the trial centre. The investigator is required to have adequate current insurance to cover claims for negligence and/or malpractice. The sponsor will provide insurance cover for the clinical trial as required by national regulations.

11.7 POST-TRIAL CARE

The subjects will remain in the study until they are discharged from the hospital. Consequently there is no requirement for post-trial care.

12 APPENDICES

12.1 REFERENCES

1: Mock C. Strengthening Care for the Injured Globally. *The Journal of Trauma: Injury, Infection, and Critical Care.* 2011;70(6):1307-1316.

2: Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. *J Trauma.* 1995;38:185–193.

3: MacLeod JBA, Lynn M, McKenney MG, Cohn SM, Murtha M. Early Coagulopathy Predicts Mortality in Trauma. *The Journal of Trauma: Injury, Infection, and Critical Care.* 2003;55(1):39–44.

4: Brohi K. Acute Traumatic Coagulopathy. *The Journal of Trauma: Injury, Infection, and Critical Care.* 2003;54(6):1127-1130.

5: Frith D, Goslings JC, Gaarder C et al. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. *Journal of Thrombosis and Haemostasis.* 2010;8(9):1919–1925.

6: Hess JR, Lindell AL, Stansbury LG, Dutton RP, Scalea TM. The prevalence of abnormal results of conventional coagulation tests on admission to a trauma center. *Transfusion.* 2009;49(1):34–39.

7: Eastridge BJ, Malone D, Holcomb JB. Early Predictors of Transfusion and Mortality After Injury: A Review of the Data-Based Literature. *The Journal of Trauma: Injury, Infection, and Critical Care.* 2006;60(Supplement):S20–S25.

8: Davenport R, Manson J, De'Ath H, et al. Functional definition and characterization of acute traumatic coagulopathy. *Critical Care Medicine.* 2011;39(12):1-7.

9: Spahn DR, Cerny V, Coats TJ, Duranteau J. Management of bleeding following major trauma: a European guideline. *Critical Care* 2007;11(2):414

10: Khan S, Davenport R, Raza I, Glasgow S. Damage control resuscitation using blood component therapy in standard doses has a limited effect on coagulopathy during trauma hemorrhage. *Intensive care Medicine* 2015;41(2):239-247.

11: Afshari A, Wikkelsø A, Brok J, Møller AM, Wetterlev J.Thrombelastography (TEG) or Thrombelastometry (ROTEM) to Monitor Haemotherapy Versus Usual Care in Patients with Massive Transfusion. *The Cochrane Library* 2011,Issue 3

12: Hunt H, Stanworth S, Curry N, Woolley T, Cooper C, Ukoumunne O, Zhelev Z, Hyde C. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. *Cochrane Database Syst Rev.* 2015 Feb 16;2:CD010438.

13: Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma. *JAMA.* 2015;313(5):471–12.

14: Johansson et al. Hemostatic resuscitation with plasma and platelets in trauma. *J Emerg Trauma Shock* 2012;5(2):120-5

15: Roberts I, Shakur H, Coats T, Hunt B. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. *Health Technology Assessment* 201;17(10):1-79.

12.2 SOFA TABLE OF ORGAN DYSFUNCTION [a]

SOFA score	0	1	2	3	4
Respirationa PaO_2/FIO_2 (mm Hg) SaO_2/FIO_2	>400	<400 221–301	<300 142–220	<200 67–141	<100 <67
Coagulation Platelets $10^3/mm^3$	>150	<150	<100	<50	<20
Liver Bilirubin (mg/dL)	<1.2	1.2–1.9	2.0–5.9	6.0–11.9	>12.0
Cardiovascularb Hypotension	No hypotension	MAP <70	Dopamine $\leq$5 or dobutamine (any)	Dopamine >5 or norepinephrine $\leq$0.1	Dopamine >15 or norepinephrine >0.1
CNS Glasgow Coma Score	15	13–14	10–12	6–9	<6
Renal Creatinine (mg/dL) or urine output (mL/d)	<1.2	1.2–1.9	2.0–3.4	3.5–4.9 or <500	>5.0 or <200

[a] *Created in a consensus meeting of the European Society of Intensive Care Medicine in 1994 and further revised in 1996.*

[b] *Adrenergic agents administrated for at least 1 hr (doses given are in µg/kg/min)*

12.3 LIST OF MANAGEMENT DOCUMENTS

The following is a list of attachments, those with an asterisk* will be submitted to the Research Ethics Committee with the protocol:

- Consent Form*
- Patient Information Sheet*
- Source Data Identification List (see *Section 10.4*)
- Core Lab Instructions To Investigators (see *Section 12.4*)

12.4 CORE LAB INSTRUCTIONS TO INVESTIGATORS

The purpose of this section is to describe requirements for study sample collection, processing and analysis.

Whole blood (20ml)

Collect 20ml whole blood in appropriate collection vessels:

- 2 x 2.7ml vacutainer (containing Sodium Citrate)   *CCT & VHA*
- 1 x 2.0ml arterial blood gas syringe   *Arterial blood gas*
- 1 x 4.0ml vacutainer (containing dipotassium EDTA)   *Full blood count*
- 1 x 5.0ml vacutainer (containing silica clot activator)   *Biochemistry*

12.5 DEFINITIONS OF TRANSFUSION REACTIONS

12.5.1   Severity of Acute Transfusion Reactions

The Investigator must assess the severity of the event according to the following terms and assessments. The intensity of an event should not be confused with the term "serious" which is a regulatory definition based on subject/event outcome criteria.

Severity Grades for Acute Transfusion Reactions			
Category	1=Mild	2=Moderate	3=Severe
Febrile type reaction	A rise in temperature up to 2^{0}C with no other signs/symptoms	A rise in temperature of 2^{0}C or more, and/or rigors, chills, other inflammatory symptoms /signs such as myalgia or nausea which precipitate stopping the transfusion	A rise in temperature of 2^{0}C or more, and/or rigors, chills, other inflammatory symptoms signs such as myalgia or nausea and/or hypotension which necessitate stopping the transfusion, medical review and/or hospital admission or prolongation of stay
Allergic type reaction	Transient flushing, urticaria or rash	Wheeze or angioedema with or without flushing /urticaria/rash but without respiratory compromise or hypotension	Bronchospasm, stridor, angioedema or circulatory problems which require urgent medical intervention and/or, directly result in or prolong hospital stay or anaphylaxis (severe life threatening,generalized or systemic hypersensitivity reaction with rapidly developing airway and/or breathing and/or circulatory problems, usually associated with skin or mucosal changes)
Reaction with both allergic and febrile features	Features of mild febrile and mild allergic reactions	Features of both allergic or febrile reactions, at least one of which is in the moderate category	Features of both allergic or febrile reactions, at least one of which is in the severe category
Hypotension		Isolated fall in systolic or diastolic pressure of 30mm or more in the absence of inflammatory, allergic or anaphylactic symptoms; no/minor intervention required	Hypotension leading to shock without allergic or inflammatory symptoms; urgent medical intervention requires

These definitions are reproduced from UK SHOT (Serious Hazards of Transfusion)

12.5.2   Non-Acute Transfusion Reactions

Category	Definition
TRALI (Transfusion related acute lung injury)	Acute dyspnoea with hypoxia and bilateral pulmonary infiltrates during or within six hours of transfusion, not due to circulatory overload or other likely cause.
TACO (Transfusion associated circulatory overload)	Any four of the following occurring within six hours of transfusion: ° Acute respiratory distress. ° Tachycardia. ° Increased blood pressure. ° Acute or worsening pulmonary oedema. ° Evidence of positive fluid balance.
TTI (Transfusion transmitted infection)	Include as a TTI if, following investigation, the recipient had evidence of infection post transfusion, and there was no evidence of infection prior to transfusion and no evidence of an alternative source of infection. Plus; **Either** at least one component received by the infected recipient was donated by a donor who had evidence of the same transmissible infection. **Or** at least one component received by the infected recipient was shown to contain the agent of infection.

These definitions are reproduced from UK SHOT (Serious Hazards of Transfusion).

iTACTIC: Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy

A multi-centre, prospective, randomised controlled study to compare outcomes of Viscoelastic Haemostatic Assay (VHA)-guided resuscitation versus optimised Conventional Coagulation Test (CCT) resuscitation support in haemorrhaging trauma patients

STATISTICAL ANALYSIS PLAN
Version 2.0
BARTS HEALTH NHS TRUST

Prepared By:

Name	Role	Signature	Date
Jacqueline Murphy	Trial statistician		02/11/2018
Roberta Maroni	Trial statistician		02/11/2018

Approved By:

Name	Role	Signature	Date
Prof. Karim Brohi	Chief Investigator	*[signature]*	07.11.2018
Dr Christine Gaarder	Co-investigator		
	TSC Chair		

Short title/Acronym:	iTACTIC

Sponsor   Queen Mary, University of London

Contact person of the above sponsor organisations is:

Dr Sally Burtles
Director of Research Services & Business Development
Joint Research Management Office
QM Innovation Building
5 Walden Street
London E1 2EF
Phone: 020 7882 7260
Email: sponsorsrep@bartshealth.nhs.uk

REC Reference   16/LO/0004

Chief Investigator: Professor Karim Brohi
Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, 4 Newark Street, Whitechapel, London, E1 12AT, UK
Phone: +44 77 0319 0545
Email: k.brohi@qmul.ac.uk

EudraCT reference: *Insert once known*

Study sites: Academic Medical Centre, Amsterdam,
The Netherlands

Kliniken der Stadt Köln gGmbH, Cologne, Germany

Rigshospitalet (Copenhagen University Hospital), Copenhagen, Denmark

John Radcliff Hospital, Oxford, United Kingdom

Oslo University Hospital, Oslo, Norway

The Royal London Hospital, London,
United Kingdom

Health Economics Research Centre,
Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom

Nottingham University Hospitals
Queens Medical Centre, Nottingham, UK

Radboud University Medical Center, Nijmegen, Netherlands

University of Kansas Hospital (UKH), Kansas City, USA

1. TRIAL SUMMARY

The main characteristics of the trial have been summarised in the iTACTIC non-CTIMP Protocol (v3.0 14.03.17). Please refer to this Protocol for full details.

|	
TITLE	A multi-centre, prospective, randomised controlled study to compare outcomes of Viscoelastic Haemostatic Assay (VHA)-guided resuscitation versus optimised Conventional Coagulation Test (CCT) resuscitation support in haemorrhaging trauma patients
SHORT TITLE	Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy (iTACTIC)
PROTOCOL VERSION/DATE	v3.0 / 14/03/2017
METHODOLOGY	Non-blinded, randomised controlled trial
STUDY DURATION	The study will enrol patients over a 24-month period. Patient follow-up, data cleaning & analysis will take a further 9 months.
TREATMENT DURATION	The subject's participation in the study will last a maximum of 28 days.
STUDY LEADS	CHIEF INVESTIGATOR: Prof Karim Brohi Centre for Trauma Sciences, Blizard Institute Queen Mary University of London, 4 Newark Street, London, E1 2AT Phone: +44 7703 190545 Email: k.brohi@qmul.ac.uk CO-INVESTIGATOR: Dr Christine Gaarder Department of Traumatology, Oslo University Hospital, 166 Kirkeveien, Oslo, NO-0424 Phone: +47 4131 8992 Email: tinagaa@ous-hf.no
PRIMARY OBJECTIVE	The primary objective is to compare the haemostatic effect of Viscoelastic Haemostatic Assays (VHA)-guided transfusion strategy versus optimized non-VHA guided transfusion strategy in haemorrhaging trauma patients.
SECONDARY OBJECTIVES	The secondary objectives of the study are to determine the effects of VHA-led versus optimized non-VHA guided resuscitation on organ failure, hospital stay, critical care stay, health care resource needs and mortality.

PHASE OF THE TRIAL	Phase 2a
NUMBER OF SUBJECTS	A total target of 392 adult male and female severely injured trauma patients with ongoing traumatic haemorrhage.
INCLUSION CRITERIA	**INCLUSION CRITERIA** A patient will be eligible for the study if they meet the following criteria: • Adult trauma patients (according to local definitions) • Present with clinical signs of haemorrhagic shock AND • Activate the local massive haemorrhage protocol and initiate first transfusion • Randomised within 3 hours of injury and 1 hour of admission to the emergency department of the participating study site • Agreement is provided on behalf of incapacitated patients by Personal Consultee or Nominated Consultee (i.e. trauma team leader)
STATISTICAL METHODOLOGY AND ANALYSIS	**ANALYSIS POPULATIONS:** The analysis populations will be defined as follows: *Intention to treat (ITT) analysis* All included patients will be analysed according to the intervention arm to which they are randomised. *Per protocol analysis* The following patients will be excluded from the per protocol analysis: • Patients who receive an intervention other than the one they were randomised to • Patients who do not have at least one VHA or Conventional Coagulation Test (CCT) performed • Patients who die within 60 minutes after baseline blood sampling • Patients who achieve haemostasis within 60 minutes of baseline sampling. **PRIMARY ENDPOINT ANALYSIS:** Difference in proportions of alive and free of massive transfusion will be examined with the Chi-square test. Absolute and Relative risk reductions between the two study arms will be calculated. **SECONDARY ENDPOINTS ANALYSES:**

	Differences in proportions will be examined with the Chi-square test. Differences between continuous variables will be assessed by difference in means and the Student's t-test, or difference in median and the Wilcoxon-Mann-Whitney test as appropriate.
Proposed Start Date	1st December 2015
Proposed End Date	30th November 2017
Study Duration	24 months

2. TRIAL OBJECTIVES

2.1 PRIMARY OBJECTIVE

The primary objective is to compare the haemostatic effect of viscoelastic haemostatic assay (VHA)-guided transfusion strategy versus optimized Conventional Coagulation Test (CCT) guided transfusion strategy in haemorrhaging trauma patients.

2.2 SECONDARY OBJECTIVE

The secondary objectives of the study are to determine the effects of VHA-led versus optimized CCT-guided resuscitation on organ failure, hospital stay, critical care stay, health care resource needs and mortality.

3. METHODOLOGY

3.1 INCLUSION CRITERIA

Adult trauma patients (according to local definitions) will be enrolled if they satisfy each of these inclusion criteria:

- Adult trauma patients (according to local definitions)
- Present with clinical signs of haemorrhagic shock
- Activate the local massive haemorrhage protocol and initiate first transfusion
- Randomised within 3 hours of injury and 1 hour of admission to the emergency department of the participating study site
- Agreement is provided on behalf of incapacitated patients by Personal Consultee or Nominated Consultee (i.e. trauma team leader)

3.2 EXCLUSION CRITERIA

Patients will be ineligible to be enrolled in the study if:

- Any inclusion criteria are not met

3.3 TRIAL INTERVENTION

The interventions to be compared are:

a) Conventional Coagulation Test (CCT) guided resuscitation
b) Viscoelastic Haemostatic Assay (VHA) guided resuscitation

3.4 STUDY SCHEME

```
┌─────────────────────────────┐
│  Trauma patient admitted to │
│    Emergency Department      │
└─────────────────────────────┘
              │
              ▼
┌─────────────────────────────┐        ┌──────────────────┐
│    Screened for eligibility  │        │  Screening data  │
│  If eligible, consent or     │        │    collection     │
│  agreement to participate    │        └──────────────────┘
│         sought.              │
└─────────────────────────────┘        ┌──────────────────┐
              │                         │    Enrolment     │
              ▼                         └──────────────────┘
┌──────┐   ┌─────────────────────┐
│  NO  │◄──│  Consent or agreement │
└──────┘   │      obtained?        │
   │       └─────────────────────┘
   ▼              │
┌──────────────┐  ▼
│  Continue    │  ┌──────┐
│  standard    │  │ YES  │
│  management  │  └──────┘
└──────────────┘     │
                     ▼
                                         ┌──────────────────┐
┌─────────────────────────┐              │    Allocation     │
│  Participant randomised  │              └──────────────────┘
│   Patient registration.  │
│     Unique study ID      │
└─────────────────────────┘
    │                    │
    ▼                    ▼
┌──────────────┐  ┌─────────────┐  ┌──────────────┐
│  VHA Group   │  │ Intervention │  │  CCT Group   │
│  VHA-led     │  └─────────────┘  │  CCT-led     │
│  therapy     │                   │  therapy     │
└──────────────┘                   └──────────────┘
        │                                 │
        ▼                                 ▼
       ┌─────────────────────────────┐    ┌──────────────────┐
       │  Completion of participation │    │  Outcome data    │
       │  Discharge from hospital,    │    │   collection      │
       │      death or Day28          │    └──────────────────┘
       └─────────────────────────────┘
┌──────────────┐       │
│ At discharge,│       ▼
│ death, or Day│  ┌──────────────┐
│ 28 whichever │  │ Primary outcome │
│  is sooner   │  │  Haemostasis  │
└──────────────┘  └──────────────┘
                        │
                        ▼
                  ┌──────────────────┐
                  │ Secondary outcome │
                  │ Clinical outcomes &│
┌──────────────┐  │  resource demands │
│ At 3 months  │  └──────────────────┘
└──────────────┘
```

3.5   RANDOMISATION AND BLINDING PROCEDURES

Enrolled patients will be block randomised per centre to either the CCT or the VHA study arm. The randomised controlled trial will be unblinded.

Once a patient is determined eligible for the study and informed consent or agreement has been obtained, each subject will be enrolled as soon as possible and will be assigned a unique study identifier; this will be used throughout the subjects' participation in the study and will be documented on the enrolment log. This unique identifier will be alphanumeric, reflecting the study, the site and commencing at '001', ascending sequentially thereafter (i.e. iTACTIC_RLH_001 etc.).

Randomisation will occur within 3 hours of injury and within one hour of admission.

24-hour on-site randomization will be performed by envelope opening, to allow for immediate allocation of subjects. An independent party, appointed by the Sponsor, will generate the randomization sequence and site envelopes centrally. These will be provided to each study site in a secure manner.

The site Investigator or designee will open a pre-sealed envelope containing the randomised treatment group allocation. Once randomised, the subject's pack details will be documented on the enrolment log.

3.6   SAMPLE SIZE CALCULATION

The planned sample size for this study is 392 patients for which the massive transfusion protocol (MTP) is activated and transfusions initiated, 196 in each study arm.

Based upon legacy registry data from the Partners, approximately 28% of patients will need massive transfusion or die. This figure decreases to an overall proportion of 15% in the VHA group (i.e. using VHA guided strategy). With a power of 80% and a two-sided alpha of 0.05, 170 patients per group are required. Assuming a drop-out rate of 15%, 196 patients are needed per group.

3.7   DATA HANDLING

3.7.1   CASE REPORT FORM

Data collection for this study will be accomplished using a paper case report form (CRF) to capture data prospectively and transferred to an electronic database (Discovere). CRFs are required and will be completed for each randomised subject. It is the Investigator's responsibility to ensure the accuracy, completeness and timeliness of the data reported on the subjects' CRF. CRFs will be completed in a timely fashion to support the study timelines. Source documentation supporting the CRF data will indicate the subject's participation in the study and document the dates and details of informed consent and study procedures. Data collected on the CRFs will be verified against the source documentation.

3.7.2 SCHEDULE OF INTERVENTION

ASSESSMENT	SCREENING & RANDOMISATION	RESUSCITATION (Every 4U RBC)	HAEMOSTASIS (1hr after last RBC)	6 HRS	24 HRS	UNTIL DAY 28 (Daily)	DISCHARGE	DAY 90
Eligibility	×							
Informed Consent	×							
Medical History	×							
Physical Exam	×	×	×	×	×			
Prior Surgery & Treatment	×							
Blood Sample	×	×	×	×	×			
Haematology	×				×			
Blood chemistry	×				×			
Arterial Blood Tests	×		×	×	×			
Conventional Coagulation Tests (CCT)	×	×	×	×	×			
Visco Haemostatic Assays (VHA)	×	×	×	×	×			
Total Blood, Coag Factor, Fluid & TXA	×	×	×	×	×			
SOFA	×				×	end ICU	×	
SAEs	×	×	×	×	×	×	×	
Mortality				×	×	×		×
Ventilator-free days						×	×	
Vasopressors days						×	×	
Renal Replacement Therapy days						×	×	
ICU days						×	×	
Hospital days						×	×	
Surgical episodes						×	×	
Thromboembolic events						×	×	
First destination							×	
Quality of Life							×	×
Current disposition								×

3.7.3 TRIAL DATA MANAGEMENT AND VERIFICATION

Quality control of data entered and data cleaning will be performed locally at each participating site and monitored by the Clinical Trial Co-ordinator. This will include cross-checking that data has been entered from the CRFs into the trial database correctly, and also performing range, data completeness and consistency checks. Once this stage is finished, the trial dataset will be declared frozen and exported from the Discovere database for final data review and validation checks by a statistician, who will raise data queries with the Clinical Trial Co-ordinator. Once the trial statistician, data manager, and trial manager are satisfied that all queries have been resolved, the database will be locked. The locked database will be exported for final analysis.

4. OUTCOME MEASURES

4.1 PRIMARY ENDPOINT

The primary endpoint is the proportion of subjects alive and free of massive transfusion* at 24 hours.

receiving 10 or more units of RBC within 24 hours

4.2 SECONDARY ENDPOINTS

The secondary endpoints listed below will be analysed in order to provide a sensitive and comprehensive description of outcomes and healthcare resource demands for the VHA and CCT arm subjects:

- All-cause mortality at 6 and 24 hours and 28 & 90 days post admission
- Duration and severity of coagulopathy until haemostasis[1], as defined by the area under the PTr curve over time[2,3] up to 24 hours
- Proportion of patients who have corrected coagulopathy (PTr ≤ 1.2) after first 8 units of RBC
- Time to haemostasis[1]
- Blood products (RBC, plasma, platelets alone and in total) 6 and 24 hours after admission
- 28-day ventilator-free days
- 28-day ICU-free days
- Total hospital length of stay
- 28-day symptomatic thromboembolic events
- Incidence of transfusion related complications
- Incidence of organ dysfunction
- Health care resource, productivity costs and HRQoL (EuroQol EQ-5D™ at discharge or day 28, and at day 90)
- Lifetime health economic cost-effectiveness of personalized VHA-guided haemorrhagic treatment versus CCT-guided

[1]*Time of haemostasis is defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary haemostasis has been achieved*

[2]*Coagulopathy defined as Prothrombin ratio (PTr) >1.2*

[3]*Patients who die will have their time of haemostasis set at 24 hours, and last PTr extrapolated to this time point.*

Note: All non-survivors (patients who die during the 28-day study period) will receive 0 days for Ventilator-free days and ICU-free days.

5. DETAILED ANALYSIS PLAN

5.1 ANALYSIS PRINCIPLES

All primary and secondary outcomes will be analysed as intention-to-treat (ITT), and will include all randomised patients for whom the primary outcome of alive and free of massive transfusion at 24 hours is recorded. A per-protocol analysis will be performed for the primary and secondary endpoints (Section 5.1.2).

Both ROTEM®-guided and TEG®-guided therapy together (i.e. VHA arm) will be compared with the CCT arm. Separate analyses will be performed for ROTEM®-guided and TEG®-guided therapy alone for primary endpoint and correction of coagulopathy outcomes only.

Sensitivity analyses around missing data will be performed for the secondary endpoints (Section 5.8).

The statistical analysis will be performed by means of Stata version 13. All applied tests will be two-sided and p-values of 0.05 will be accepted as statistically significant. The analyses for the secondary endpoints will be adjusted for multiple testing (Bonferroni correction).

5.1.1 DEFINITION OF INTENTION–TO-TREAT POPULATION

This will include all consented patients randomised for whom the primary outcome is recorded, with results presented according to the arm they were randomised to, regardless of whether they did or did not have at least one ROTEM®/TEG®/CCT (depending upon trial arm) performed or whether they had the incorrect procedure performed. Any patients withdrawn from the study will be included in the analyses where data was collected and is still available.

5.1.2 DEFINITION OF PER PROTOCOL POPULATION

This will include all consented patients receiving their randomised intervention, for whom the primary outcome is recorded, who had at least one ROTEM®/TEG®/CCT (depending upon trial arm) performed and survived for more than (>) 60 minutes after baseline sampling and did not achieve haemostasis[1] for within (≤) 60 minutes after baseline sampling. Any patients withdrawn from the study will be included in the analyses where data was collected and is still available.

The following patients will be excluded from the per protocol analysis:

- Patients who receive an intervention other than the one they were randomised to

- Patients who do not have at least one ROTEM®/TEG®/CCT test performed
- Patients who die within 60 minutes after baseline blood sampling
- Patients who achieve haemostasis within 60 minutes of baseline sampling

[1]*Time of haemostasis is defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary haemostasis has been achieved*

5.2 ANALYSIS OF KEY PATIENT DEMOGRAPHICS AND CLINICAL CHARACTERISTICS

A CONSORT diagram will be presented to show how patients progressed through the trial. The number (%) of subjects who withdraw from the study and their reasons for withdrawal will be displayed by treatment group.

The key demographics and clinical condition of the patients will be presented for each arm of the trial to describe the cohort.

Patient characteristics will also be summarised by site to allow visual assessment of differences between sites to be assessed.

5.3 ANALYSIS OF PRIMARY OUTCOME MEASURES

The primary endpoint of alive and free of massive transfusion at 24 hours will be assessed by logistic regression to produce odds ratios with 95% confidence intervals. Absolute and Relative risk reductions between the two study arms will be calculated. As a sensitivity analysis, the regression will include adjustment for centre. The primary and secondary endpoints will be assessed by ITT and per protocol, in addition to a subgroup analysis by ITT for the primary endpoints.

5.4 ANALYSIS OF SECONDARY OUTCOME MEASURES

Differences in secondary endpoints (as defined in section 4.2) will be analysed by ITT and per protocol.

5.4.1 MORTALITY AT 6H, 24H, 28 DAYS AND 90 DAYS

A log rank test will be performed on all-cause mortality at 6 and 24 hours as well as 28 and 90 days post admission to compare the two study arms.

5.4.2 DURATION AND SEVERITY OF COAGULOPATHY

Time spent in a coagulopathic condition (PTr>1.2) from injury until heamostasis[1] up to 24 hours will be summarised for each study arm and compared using a Wilcoxon-Mann-Whitney test.

Severity of coagulopathy (PTr>1.2) until haemostasis is defined as the area under the PTr curve[2] over time for each individual patient up to 24 hours. It will be calculated using the trapezoidal rule as an approximation. Differences between the two study arms for area under the curve will be examined using a two-sample t-test or the Wilcoxon-Mann-Whitney test.

[1] Time of haemostasis is defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary haemostasis has been achieved

[2] Patients who die will have their time of haemostasis set at 24 hours, and last PTr extrapolated to this time point.

5.4.3 CORRECTION OF COAGULOPATHY AFTER 8 UNITS RBC

For those patients who have received at least 8 units of RBCs, the proportion of those who have corrected coagulopathy ($PTr \leq 1.2$) will be compared using the Chi-squared test (or Fisher's exact test if this subgroup has less than 20 patients and less than 5 patients experience or do not experience the outcome).

5.4.4 TIME TO HAEMOSTASIS

The time from injury to haemostasis[1] will be calculated for each individual and the mean time with 95% confidence interval estimated per arm. Student's t-test or the Wilcoxon- Mann-Whitney test will be performed to compare time from injury to haemostasis in the two study groups.

[1] Time of haemostasis is defined as having occurred at the end of the first hour free of red cell transfusions and the treating clinicians believe primary haemostasis has been achieved

5.4.5 TOTAL BLOOD PRODUCTS

The total number of blood products (RBC, plasma, platelets alone and in total) transfused will be summarised for each arm for all patients at 6 hours and 24 hours after injury and compared between arms using a Wilcoxon- Mann-Whitney test.
The change from baseline in the total number of blood products transfused at 6 hours will be analysed using the van Elteren test stratified by study centres.
The change from baseline in the total number of blood products transfused at 24 hours will be analysed similarly.

5.4.6 28-DAY VENTILATOR-FREE DAYS

Calculated as 28 – [number of ventilated days] for each individual and summarised for each arm of the trial. All negative results are expressed as 0 days. All non-survivors (patients who die during the 28-day study period) will receive 0 days for ventilator-free days. The two values for the two study groups will be compared using a Wilcoxon-Mann-Whitney test.

5.4.7 28-DAY ICU FREE DAYS

Calculated as 28 – [number of ICU days] for each individual and summarised for each arm of the trial. All negative results are expressed as 0 days. All non-survivors (patients who die during the 28-day study period) will receive 0 days for ICU-free days. The outcome for the two study groups will be compared using a Wilcoxon-Mann-Whitney test.

5.4.8   TOTAL HOSPITAL LENGTH OF STAY

The total hospital length of stay (up to 28 days) will be summarised for each study arm. Length of stay for the index hospitalisation up to 28 days will be compared between groups using Kaplan-Meier methods and the log rank test.

5.4.9   THROMBOTIC EVENTS

The total number of thrombotic events of each type occurring within 28 days will be summarised for patients in each arm of the trial, and reported along with the number of patients affected and total follow-up time (i.e. until death or 28 days). The rate of thrombotic events will be compared between groups using a Poisson rate model taking into account person-days at risk.

5.4.10   INCIDENCE OF TRANSFUSION-RELATED COMPLICATIONS

All non-acute transfusion reactions will be summarised for each arm of the trial, and reported along with the number of reactions per day at risk.
All acute transfusion reactions related to cryoprecipitate will be summarised for each arm of the trial, and reported along with the number of reactions per day at risk.
The rate of complications by type of reaction (non-acute or acute) will be compared between the two study groups using a Poisson rate model taking into account person-days at risk.

5.4.11   INCIDENCE OF ORGAN DYSFUNCTION

The cumulative incidence of single or multi-organ failure at day 28 in each arm of the trial will be estimated from an unadjusted cumulative incidence function with death as a competing risk.

5.4.12   HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE

Scores from the EuroQol EQ-5D™ questionnaire at discharge or day 28, and at day 90 will be summarised for each arm of the trial.

5.4.13   ECONOMIC OUTCOMES

Health care resource use, productivity costs, and lifetime cost-effectiveness will be analysed separately as part of the health economic analysis.

5.5   OTHER OUTCOME MEASURES

SAEs: the number and type of all SAEs reported will be summarised for patients in each arm of the trial. Available data from patients who do not consent to remain as part of the trial will still be included within the safety analysis. Number of SAEs between the two arms will be compared using a Wilcoxon-Mann-Whitney test.

Surgical procedures: the number of surgical procedures will be summarised for patients in each arm of the trial.

Bleeding episodes: the number of bleeding episodes will be summarised for patients in each arm of the trial.

5.6   SUBGROUP ANALYSIS BY SITE

An ITT analysis for primary and secondary endpoints will also be presented by study site.

5.7   SUBGROUP ANALYSES

The following patient categories will be analysed by ITT for the primary outcome only:

- Patients with severe traumatic brain injury (defined as brain AIS 4, 5 or 6)
- Patients without severe traumatic brain injury (defined as brain AIS $\leq$4)
- Patients with known pre-existing coagulopathy (PTr >1.2)
- Prior oral anticoagulant therapy (except for aspirin)
- Patients who received a massive transfusion (10 or more RBC units in the first 24 hours)
- Patients arriving coagulopathic

5.8   SENSITIVITY ANALYSES

Missing data are not expected for the primary outcome. Sensitivity analysis for secondary outcomes will be carried out using multiple imputation for missing data in order to assess the impact of missing data on the results. The number (n) of multiply imputed data sets will be in line with the greatest proportion of observed missing data in the outcome variables. For example, if the largest proportion of observed missing data in any outcome variable is approximately 10%, then n=10 replicate data sets will be produced (1). Rubin's rules will be used to combine the results from the n data sets and provide the final estimate. The extent to which the missing data satisfy the Missing at Random assumption will be reported.

5.9   PROCEDURE FOR HANDLING MISSING DATA, PROTOCOL VIOLATIONS, PATIENTS RANDOMISED IN ERROR AND LOSSES TO FOLLOW-UP

The effect of missing data for key outcome measures will be assessed as described using sensitivity analyses.

The primary and secondary analyses will be by intention-to-treat and per protocol analysis, excluding any patients for whom there were protocol deviations or violations in the arm they were randomised to.

<u>DEFINITIONS</u>

Protocol Deviation: Accidental or unintentional changes to, or non-compliance with the research protocol that does not increase risk or decrease benefit or; does not have a significant effect on the subject's rights, safety or welfare; and/or on the integrity of the data. Deviations may result from the action of the subject, researcher, or research staff.

Examples of a deviation include:

- A scheduled study visit not taking place

- Failure to collect the EuroQol EQ-5D™ questionnaire

- Subject's refusal to complete scheduled research activities

Protocol Violation: Accidental or unintentional change to, or non-compliance with the IRB approved protocol without prior sponsor and IRB approval. Violations generally increase risk or decrease benefit, affect the subject's rights, safety, or welfare, or the integrity of the data.

Examples of protocol violations:

- Failure to obtain valid informed consent (e.g., obtained informed consent on a form which has not been ethically approved)

- Incorrect assignment of treatment intervention (e.g. a participant in the CCT arm having a VHA analysis performed during the intervention period)

- Not following inclusion/exclusion criteria

Patients withdrawn from the study or lost to follow-up at any point after the primary outcome data were recorded will be included in any analyses for which outcome data is available, and excluded from all other analyses. Patient withdrawal, including reasons for withdrawal, and loss to follow-up will be described by study arm to enable assessment of any selection bias.

5.10 INTERIM ANALYSIS

A pre-defined interim analysis will be performed after the enrolment of 100 patients, including an assessment of recruitment logistics with the possibility to revise the planned sample size.

An Independent Data Monitoring Committee (IDMC) will review all data on outcome of the patients in the respective treatment arms. The IDMC will focus on adherence to protocol, and present pre-specified criteria that need to be fulfilled regarding safety of the patients for the study to continue.

6. DATA ANALYSIS TABLES AND FIGURES TO BE COMPLETED

Figure 1: CONSORT Flow Diagram

Table 1: Trial Recruitment Characteristics

Table 2: Baseline Characteristics of Eligible Patients

Table 3: Outcomes (primary and secondary)

Table 4: Serious Adverse Events

Table 1 (section B) will be presented for each of the six individual recruiting sites and for all sites combined.

Tables 2, 3 and 4 will be presented as ITT. A PP analysis will additionally be presented for Table 2 & Table 3.

Tables 2, 3 and 4 will be produced for each of the six individual recruiting sites and for all sites combined.

Tables 2 and 3 will also be presented for each subgroup (ITT only).

Tables 2 and 3 (primary endpoint and correction of coagulopathy only) will also be presented by type of VHA (ROTEM and TEG) for all sites combined.

Tables 2 and 3 will be presented using multiply imputed data as a sensitivity analysis (ITT only).

6.1 FIGURE 1: CONSORT FLOW DIAGRAM

Template available from www.consort-statement.org/consort-statement/flow-diagram

CONSORT 2010 Flow Diagram

6.2 **TABLE 1: TRIAL RECRUITMENT CHARACTERISTICS**

TABLE 1A: Patient recruitment

	Site						
	RLH	OSL	CPH	OXF	AMC	COL	All Patients
Total number of code red trauma call activations assessed for eligibility during trial period							
Number of patients eligible for trial: n (% of those assessed)							
Number of patients consented and enrolled: n (% of those eligible)							
Patients withdrawn: n (% of those enrolled)							

TABLE 1B: Intervention compliance & follow-up

	Intervention			
	CCT	VHA (ROTEM)	VHA (TEG)	VHA (ROTEM + TEG)
Randomised				
Patients with CCT or VHA performed (at least one test): n (% of those randomised)				
Lost to follow-up: n (% of those randomised)				
Patients completing the study: n (% of those randomised)				

6.3   TABLE 2: BASELINE CHARACTERISTICS OF ELIGIBLE PATIENTS

Table: Baseline characteristics by intervention (ITT)

Characteristics median (IQR)[min,max] unless otherwise stated	CCT N=	VHA (ROTEM + TEG combined) N=	ROTEM N=	TEG N=
Sex, male: n (%)				
Age (years)				

Injury Type:
    Blunt n (%)
    Penetrating n (%)				

Injury Severity Score (ISS)				
Abbreviated Injury Scale (AIS) Head & Neck				
AIS Face				
AIS Thorax				
AIS Abdo / Pelvis				
AIS Extremity				
AIS External				
Time from injury to admission (minutes)				
Glasgow Coma Scale (GCS) on scene				
Heart rate on scene (per minute)				
Systolic blood pressure (BP) on scene (mmHg)				
Respiratory rate on scene (per minute)				
GCS at admission				
Heart rate at admission (per minute)				
Systolic BP at admission (mmHg)				
Respiratory rate on admission (per minute)				
Temperature on admission (degrees Celsius)				
pH at admission				
Base excess (BE) at admission				
Lactate at admission				

Tranexamic Acid (TXA):
    Pre-hospital bolus given: n (%)
    In hospital bolus given: n (%)
    Infusion given: n (%)				

Baseline crystalloid (ml)				
Baseline colloid (ml)				
Baseline hypertonic saline (ml)				
Baseline RBC (units)				
Baseline Fresh Frozen Plasma (FFP) / Octaplas (units)				
Baseline Platelets (pools)				
Baseline Cryoprecipitate (pools)				
First 24 hour total crystalloid (ml)				
First 24 hour total colloid (ml)				

Table: Baseline characteristics by intervention (PP)
Table: Baseline characteristics by intervention and by site (ITT, CCT vs. VHA only)
Table: Baseline characteristics for each subgroup (ITT, CCT vs. VHA only)

6.4   TABLE 3: OUTCOMES

Table: Primary and secondary outcomes by study arm (ITT, all patients)

Outcomes median (IQR)[min,max] unless otherwise stated	CCT N=	VHA (ROTEM + TEG combined) N=	Difference & p-value
PRIMARY OUTCOME			
Patients alive & free of massive transfusion at 24 hours: n (%)			
SECONDARY OUTCOMES			
Mortality at 6 hours: n (%)			
Mortality at 24 hours: n (%)			
Mortality at 28 days: n (%)			
Mortality at 90 days: n (%)			
Duration & severity of coagulopathy until haemostasis [AUC: PTr vs time]			
Patients with correction of coagulopathy after first 8 units RBC: n (%)			
Time to haemostasis (min)			
Time spent coagulopathic until haemostasis			
Total RBC in first 6 hours (units)			
Total FFP / Octaplas in first 6 hours (units)			
Total Platelets in first 6 hours (pools)			
Total Cryoprecipitate in first 6 hours (pools)			
Total Fibrinogen concentrate in first 6 hours (g)			
Total number of blood products in first 6 hours (RBC + plasma + platelets)			
Total RBC in first 24 hours (units)			
Total FFP / Octaplas in first 24 hours (units)			
Total Platelets in first 24 hours (pools)			
Total Cryoprecipitate in first 24 hours (pools)			
Total Fibrinogen concentrate in first 24 hours (g)			
Total number of blood products in first 24 hours (RBC + plasma + platelets)			
Total dose of TXA in first 24 hours (g)			
28-day ventilator Free Days			
28-day ICU Free Days			
Total Hospital LOS			
28-day symptomatic thromboembolic events			
Number of non-acute transfusion reactions: n			
Number of acute transfusion reactions: n			
Incidence of multiple organ dysfunction: n (%)			
Surgical procedures per patient			
Bleeding episodes after haemostasis			
EQ-5D™ at discharge / day 28			
EQ-5D™ at 90 days			

Table: Primary outcome by study arm (PP, all patients)
Table: Primary and secondary endpoints by study arm (ITT, by site)
Table: Primary endpoints by study arm (ITT, for each subgroup)
Table: Primary endpoint and correction of coagulopathy (ITT, by type of VHA vs. CCT)
Table: Secondary outcomes by intervention using multiply imputed data (ITT, all patients)

6.5   TABLE 4: ALL SERIOUS ADVERSE EVENTS at 28 days

Table: SAEs by study arm (all sites)

All patients CCT			All patients VHA		
Total number of SAEs: n			Total number of SAEs: n		
Total number of patients with one or more SAEs: n (% of patients in arm)			Total number of patients with one or more SAEs: n (% of patients in arm)		
SAE description	Number of events: n (% of all events)	Number of patients: n (% of patients in arm)	SAE description	Number of events: n (% of all events)	Number of patients: n (% of patients in arm)

Table: SAEs by study arm (each site individually)

7.   STATISTICAL ANALYSIS PLAN AMENDMENTS

Version Number	Author	Date	Reason for Revision	Changes made since previous version
2.0	Jacqueline Murphy Roberta Maroni	02/11/2018	Updates to the planned statistical methods upon change of trial statistician	• Corrections to wording to align with study protocol and to clarify subgroup and ITT/PP definitions • Clarification over which combinations of ITT/PP, subgroup, and by-site analyses will be performed • Revision of planned statistical tests (section 5) • Revision of planned outcome table layouts (section 6) • Re-ordering of sections for clarity

8.   References

1.   White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Statistics in medicine. 2011;30(4):377-99.